You can’t get there from here

Article Type
Changed
Display Headline
You can’t get there from here

Readers of this column may recall that we have been following the fate of a small 14 primary care physician–owned accountable care organization bordering the Rio Grande River in Texas, the Rio Grande Valley Health Alliance. These physicians in 12 practices started with no infrastructure, no common electronic health records, or capital, and nonetheless took the plunge to become a Medicare Shared Savings Program accountable care organization beginning Jan. 1, 2013. It is time for an update on them.

Admittedly, I have been dragging my feet about an update, not because the results were poor, but because they were so great. With barely the minimum 5,000 beneficiaries, they saved more than $6 million in their first year. They are in the no-downside-risk plan, and thus got 50% of those savings. They have had time in 2014 to crunch the data even more to identify the 10% of patients driving more than 50% of costs and begin implementing complex high-risk patient management. For these reasons, I wager that they will do even better in 2014 through increased efficiencies.

Dr. Julian D. Bobbit

How about quality? In the first year in the Medicare Shared Savings Program (MSSP), an ACO need only show the ability to report; they are not graded on their quality performance. But the Rio Grande Valley Health Alliance kept track internally, and the ACO regularly appears to be hitting the 90th percentile on the bulk of the 33 quality metrics. Their model tracked the elements for success outlined in previous columns.

So, why have I been I hesitant to report this?

Well, so many of you readers have called or written me to say that, while this type of physician-driven community or rural ACO with a primary care core makes sense, there is no way that you can get the money to organize and build the infrastructure necessary to succeed like RGVHA has. You would have to create a legal entity and apply to a program such as the MSSP, create infrastructure, track savings over a calendar year, then wait 6 or 8 months to get the results and the shared savings payment.

In sum, it’s a great idea. You are in the best position to drive high-value health improvement. You are located where the historic lack of access and medical infrastructure has resulted in high avoidable costs.

But the cruel irony is that, thanks to the fee-for-service system, those in the best position to drive value – primary care physicians – are in the worst position to front the necessary capital costs.

RGVHA was able to go forward because they were eligible for the now-gone Advance Payment Model program that advanced them the necessary operational costs. Their exciting success would ring hollow as a message to you if you couldn’t get this type of developmental financial support. Deferred shared savings and improved quality for your Medicare patients is a great concept – but this is a proverbial “you can’t get there from here” dilemma.

The CMS ACO investment model

The Centers for Medicare and Medicaid Services also saw this disconnect. So, CMS announced a new upfront infrastructure support program specifically to promote new small nonhospital* or managed care ACOs, rural ACOs, ACOs where there is low ACO penetration, and existing ACOs wanting to move toward taking financial risk. This prepaid shared savings builds on the Advance Payment Model program.

ACOs that plan to apply for the program in the next cycle and start in 2016 must have a preliminary prospective beneficiary assignment of 10,000 or less. CMS will give preference to new ACOs in rural or low-penetration areas, or in areas with exceptional need, or to ACOs with compelling proposals on how they would invest their funds and the CMS funds.

Each dollar given by CMS is a prepayment against the ACO’s shared savings distribution. If there are not enough shared savings, there is no further repayment obligation unless the ACO leaves the program before the 3-year program period.

Applications will be accepted during the summer of 2015, which is roughly the same time as the MSSP application period.

In my mind, this is the single best investment in improving health delivery and reining in runaway health care costs that CMS could have made. It will empower those in the best position to generate the highest quality at the lowest cost: readers like you.

This could be a game changer for primary care and rural care. But it won’t happen without physician leaders like those at RGVHA. The summer of 2015 seems a long way off, but the time to begin preparing your fully financed ACO is now!

 

 

* Exceptions to the nonhospital condition exist for critical access hospitals or inpatient prospective payment hospitals with 100 or fewer beds.

Mr. Bobbitt is a senior partner and head of the Health Law Group at the Smith Anderson law firm in Raleigh, N.C. He has many years’ experience assisting physicians form integrated delivery systems. He has spoken and written nationally to primary care physicians on the strategies and practicalities of forming or joining ACOs. This article is meant to be educational and does not constitute legal advice. For additional information, readers may contact the author at [email protected] or 919-821-6612.

References

Author and Disclosure Information

Publications
Legacy Keywords
ACO, CMS, health reform, accountable care organization
Sections
Author and Disclosure Information

Author and Disclosure Information

Readers of this column may recall that we have been following the fate of a small 14 primary care physician–owned accountable care organization bordering the Rio Grande River in Texas, the Rio Grande Valley Health Alliance. These physicians in 12 practices started with no infrastructure, no common electronic health records, or capital, and nonetheless took the plunge to become a Medicare Shared Savings Program accountable care organization beginning Jan. 1, 2013. It is time for an update on them.

Admittedly, I have been dragging my feet about an update, not because the results were poor, but because they were so great. With barely the minimum 5,000 beneficiaries, they saved more than $6 million in their first year. They are in the no-downside-risk plan, and thus got 50% of those savings. They have had time in 2014 to crunch the data even more to identify the 10% of patients driving more than 50% of costs and begin implementing complex high-risk patient management. For these reasons, I wager that they will do even better in 2014 through increased efficiencies.

Dr. Julian D. Bobbit

How about quality? In the first year in the Medicare Shared Savings Program (MSSP), an ACO need only show the ability to report; they are not graded on their quality performance. But the Rio Grande Valley Health Alliance kept track internally, and the ACO regularly appears to be hitting the 90th percentile on the bulk of the 33 quality metrics. Their model tracked the elements for success outlined in previous columns.

So, why have I been I hesitant to report this?

Well, so many of you readers have called or written me to say that, while this type of physician-driven community or rural ACO with a primary care core makes sense, there is no way that you can get the money to organize and build the infrastructure necessary to succeed like RGVHA has. You would have to create a legal entity and apply to a program such as the MSSP, create infrastructure, track savings over a calendar year, then wait 6 or 8 months to get the results and the shared savings payment.

In sum, it’s a great idea. You are in the best position to drive high-value health improvement. You are located where the historic lack of access and medical infrastructure has resulted in high avoidable costs.

But the cruel irony is that, thanks to the fee-for-service system, those in the best position to drive value – primary care physicians – are in the worst position to front the necessary capital costs.

RGVHA was able to go forward because they were eligible for the now-gone Advance Payment Model program that advanced them the necessary operational costs. Their exciting success would ring hollow as a message to you if you couldn’t get this type of developmental financial support. Deferred shared savings and improved quality for your Medicare patients is a great concept – but this is a proverbial “you can’t get there from here” dilemma.

The CMS ACO investment model

The Centers for Medicare and Medicaid Services also saw this disconnect. So, CMS announced a new upfront infrastructure support program specifically to promote new small nonhospital* or managed care ACOs, rural ACOs, ACOs where there is low ACO penetration, and existing ACOs wanting to move toward taking financial risk. This prepaid shared savings builds on the Advance Payment Model program.

ACOs that plan to apply for the program in the next cycle and start in 2016 must have a preliminary prospective beneficiary assignment of 10,000 or less. CMS will give preference to new ACOs in rural or low-penetration areas, or in areas with exceptional need, or to ACOs with compelling proposals on how they would invest their funds and the CMS funds.

Each dollar given by CMS is a prepayment against the ACO’s shared savings distribution. If there are not enough shared savings, there is no further repayment obligation unless the ACO leaves the program before the 3-year program period.

Applications will be accepted during the summer of 2015, which is roughly the same time as the MSSP application period.

In my mind, this is the single best investment in improving health delivery and reining in runaway health care costs that CMS could have made. It will empower those in the best position to generate the highest quality at the lowest cost: readers like you.

This could be a game changer for primary care and rural care. But it won’t happen without physician leaders like those at RGVHA. The summer of 2015 seems a long way off, but the time to begin preparing your fully financed ACO is now!

 

 

* Exceptions to the nonhospital condition exist for critical access hospitals or inpatient prospective payment hospitals with 100 or fewer beds.

Mr. Bobbitt is a senior partner and head of the Health Law Group at the Smith Anderson law firm in Raleigh, N.C. He has many years’ experience assisting physicians form integrated delivery systems. He has spoken and written nationally to primary care physicians on the strategies and practicalities of forming or joining ACOs. This article is meant to be educational and does not constitute legal advice. For additional information, readers may contact the author at [email protected] or 919-821-6612.

Readers of this column may recall that we have been following the fate of a small 14 primary care physician–owned accountable care organization bordering the Rio Grande River in Texas, the Rio Grande Valley Health Alliance. These physicians in 12 practices started with no infrastructure, no common electronic health records, or capital, and nonetheless took the plunge to become a Medicare Shared Savings Program accountable care organization beginning Jan. 1, 2013. It is time for an update on them.

Admittedly, I have been dragging my feet about an update, not because the results were poor, but because they were so great. With barely the minimum 5,000 beneficiaries, they saved more than $6 million in their first year. They are in the no-downside-risk plan, and thus got 50% of those savings. They have had time in 2014 to crunch the data even more to identify the 10% of patients driving more than 50% of costs and begin implementing complex high-risk patient management. For these reasons, I wager that they will do even better in 2014 through increased efficiencies.

Dr. Julian D. Bobbit

How about quality? In the first year in the Medicare Shared Savings Program (MSSP), an ACO need only show the ability to report; they are not graded on their quality performance. But the Rio Grande Valley Health Alliance kept track internally, and the ACO regularly appears to be hitting the 90th percentile on the bulk of the 33 quality metrics. Their model tracked the elements for success outlined in previous columns.

So, why have I been I hesitant to report this?

Well, so many of you readers have called or written me to say that, while this type of physician-driven community or rural ACO with a primary care core makes sense, there is no way that you can get the money to organize and build the infrastructure necessary to succeed like RGVHA has. You would have to create a legal entity and apply to a program such as the MSSP, create infrastructure, track savings over a calendar year, then wait 6 or 8 months to get the results and the shared savings payment.

In sum, it’s a great idea. You are in the best position to drive high-value health improvement. You are located where the historic lack of access and medical infrastructure has resulted in high avoidable costs.

But the cruel irony is that, thanks to the fee-for-service system, those in the best position to drive value – primary care physicians – are in the worst position to front the necessary capital costs.

RGVHA was able to go forward because they were eligible for the now-gone Advance Payment Model program that advanced them the necessary operational costs. Their exciting success would ring hollow as a message to you if you couldn’t get this type of developmental financial support. Deferred shared savings and improved quality for your Medicare patients is a great concept – but this is a proverbial “you can’t get there from here” dilemma.

The CMS ACO investment model

The Centers for Medicare and Medicaid Services also saw this disconnect. So, CMS announced a new upfront infrastructure support program specifically to promote new small nonhospital* or managed care ACOs, rural ACOs, ACOs where there is low ACO penetration, and existing ACOs wanting to move toward taking financial risk. This prepaid shared savings builds on the Advance Payment Model program.

ACOs that plan to apply for the program in the next cycle and start in 2016 must have a preliminary prospective beneficiary assignment of 10,000 or less. CMS will give preference to new ACOs in rural or low-penetration areas, or in areas with exceptional need, or to ACOs with compelling proposals on how they would invest their funds and the CMS funds.

Each dollar given by CMS is a prepayment against the ACO’s shared savings distribution. If there are not enough shared savings, there is no further repayment obligation unless the ACO leaves the program before the 3-year program period.

Applications will be accepted during the summer of 2015, which is roughly the same time as the MSSP application period.

In my mind, this is the single best investment in improving health delivery and reining in runaway health care costs that CMS could have made. It will empower those in the best position to generate the highest quality at the lowest cost: readers like you.

This could be a game changer for primary care and rural care. But it won’t happen without physician leaders like those at RGVHA. The summer of 2015 seems a long way off, but the time to begin preparing your fully financed ACO is now!

 

 

* Exceptions to the nonhospital condition exist for critical access hospitals or inpatient prospective payment hospitals with 100 or fewer beds.

Mr. Bobbitt is a senior partner and head of the Health Law Group at the Smith Anderson law firm in Raleigh, N.C. He has many years’ experience assisting physicians form integrated delivery systems. He has spoken and written nationally to primary care physicians on the strategies and practicalities of forming or joining ACOs. This article is meant to be educational and does not constitute legal advice. For additional information, readers may contact the author at [email protected] or 919-821-6612.

References

References

Publications
Publications
Article Type
Display Headline
You can’t get there from here
Display Headline
You can’t get there from here
Legacy Keywords
ACO, CMS, health reform, accountable care organization
Legacy Keywords
ACO, CMS, health reform, accountable care organization
Sections
Article Source

PURLs Copyright

Inside the Article

Checklists to Improve Laser Practices

Article Type
Changed
Display Headline
Checklists to Improve Laser Practices

Hamilton and Dover (Dermatol Surg. 2014;40:1173-1174) discussed the use of checklists for improving laser and light-based procedures in their November 2014 editorial. The authors discussed how the use of checklists has become pervasive in many fields of medicine, including surgery. However, they also highlighted that the utility of checklists and their success do not come from just checking off boxes but rather from actively performing the tasks. The implementation of a laser checklist can seem daunting, but Hamilton and Dover proposed that for a dermatology practice or dermatology department it becomes easier because the dermatologist and staff work closely already, making communication less of a challenge. Also, the procedure lends itself to a systematic approach. In doing so, one can routinely ensure that the necessary practices are being done to ensure both patient and staff safety. 

 

What’s the issue?

The implementation of checklists for medical procedures may seem straightforward; however, to be effective there has to be pertinent information gathered or actions taken. Our department utilizes checklists for our laser procedures. The different steps that we have included help to ensure that the nurses who prepare the patients will communicate the pertinent information to the physician. Our checklist starts with ensuring proper setup, such as connecting the necessary pieces, before starting the laser. Next is making sure all the necessary equipment is in place, such as the correct laser goggles for the patient and staff. We label all of our goggles with the name of the laser on them so it is readily apparent what to use. We also have a check box that ensures the proper signage is outside on the door and the laser shades are drawn. There also is a section relating to the patient. Depending on the type of laser being utilized the checklist may include the following: skin type, recent history of tanning, history of oral herpes, isotretinoin use, and time since last treatment. The next check box ensures consent is signed and pretreatment photographs are taken. Any prior complications also are noted. We have a section for treatment parameters used during the current visit and then another section for posttreatment instructions.

Although a checklist may seem like unnecessary work, we found that it actually helps to enhance productivity and ensures proper laser safety for the physician and patient. We have a different one for each laser, as it also serves as a documentation tool for the procedure. Do you utilize checklists for your laser procedures? If so, what else do you include?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
laser and light-based devices; quality improvement; checklists; laser procedure
Sections
Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Related Articles

Hamilton and Dover (Dermatol Surg. 2014;40:1173-1174) discussed the use of checklists for improving laser and light-based procedures in their November 2014 editorial. The authors discussed how the use of checklists has become pervasive in many fields of medicine, including surgery. However, they also highlighted that the utility of checklists and their success do not come from just checking off boxes but rather from actively performing the tasks. The implementation of a laser checklist can seem daunting, but Hamilton and Dover proposed that for a dermatology practice or dermatology department it becomes easier because the dermatologist and staff work closely already, making communication less of a challenge. Also, the procedure lends itself to a systematic approach. In doing so, one can routinely ensure that the necessary practices are being done to ensure both patient and staff safety. 

 

What’s the issue?

The implementation of checklists for medical procedures may seem straightforward; however, to be effective there has to be pertinent information gathered or actions taken. Our department utilizes checklists for our laser procedures. The different steps that we have included help to ensure that the nurses who prepare the patients will communicate the pertinent information to the physician. Our checklist starts with ensuring proper setup, such as connecting the necessary pieces, before starting the laser. Next is making sure all the necessary equipment is in place, such as the correct laser goggles for the patient and staff. We label all of our goggles with the name of the laser on them so it is readily apparent what to use. We also have a check box that ensures the proper signage is outside on the door and the laser shades are drawn. There also is a section relating to the patient. Depending on the type of laser being utilized the checklist may include the following: skin type, recent history of tanning, history of oral herpes, isotretinoin use, and time since last treatment. The next check box ensures consent is signed and pretreatment photographs are taken. Any prior complications also are noted. We have a section for treatment parameters used during the current visit and then another section for posttreatment instructions.

Although a checklist may seem like unnecessary work, we found that it actually helps to enhance productivity and ensures proper laser safety for the physician and patient. We have a different one for each laser, as it also serves as a documentation tool for the procedure. Do you utilize checklists for your laser procedures? If so, what else do you include?

We want to know your views! Tell us what you think.

Hamilton and Dover (Dermatol Surg. 2014;40:1173-1174) discussed the use of checklists for improving laser and light-based procedures in their November 2014 editorial. The authors discussed how the use of checklists has become pervasive in many fields of medicine, including surgery. However, they also highlighted that the utility of checklists and their success do not come from just checking off boxes but rather from actively performing the tasks. The implementation of a laser checklist can seem daunting, but Hamilton and Dover proposed that for a dermatology practice or dermatology department it becomes easier because the dermatologist and staff work closely already, making communication less of a challenge. Also, the procedure lends itself to a systematic approach. In doing so, one can routinely ensure that the necessary practices are being done to ensure both patient and staff safety. 

 

What’s the issue?

The implementation of checklists for medical procedures may seem straightforward; however, to be effective there has to be pertinent information gathered or actions taken. Our department utilizes checklists for our laser procedures. The different steps that we have included help to ensure that the nurses who prepare the patients will communicate the pertinent information to the physician. Our checklist starts with ensuring proper setup, such as connecting the necessary pieces, before starting the laser. Next is making sure all the necessary equipment is in place, such as the correct laser goggles for the patient and staff. We label all of our goggles with the name of the laser on them so it is readily apparent what to use. We also have a check box that ensures the proper signage is outside on the door and the laser shades are drawn. There also is a section relating to the patient. Depending on the type of laser being utilized the checklist may include the following: skin type, recent history of tanning, history of oral herpes, isotretinoin use, and time since last treatment. The next check box ensures consent is signed and pretreatment photographs are taken. Any prior complications also are noted. We have a section for treatment parameters used during the current visit and then another section for posttreatment instructions.

Although a checklist may seem like unnecessary work, we found that it actually helps to enhance productivity and ensures proper laser safety for the physician and patient. We have a different one for each laser, as it also serves as a documentation tool for the procedure. Do you utilize checklists for your laser procedures? If so, what else do you include?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
Checklists to Improve Laser Practices
Display Headline
Checklists to Improve Laser Practices
Legacy Keywords
laser and light-based devices; quality improvement; checklists; laser procedure
Legacy Keywords
laser and light-based devices; quality improvement; checklists; laser procedure
Sections
Disallow All Ads
Alternative CME

The Top 100

Article Type
Changed
Display Headline
The Top 100

 

 

In the October 2014 issue of the Journal of Clinical and Aesthetic Dermatology (2014;7:10-19), Wu et al published the top 100 most-cited psoriasis articles in clinical dermatologic journals from 1970 to 2012. Given the explosion of literature in this area, I was very excited to rush to find the list online.  

The authors conducted a citation analysis of major clinical dermatologic journals from 1970 to 2012 limited to the subject of psoriasis. They used the search term psoriasis in the Science Citation Index from 1970 to 2012 and included articles that have received 100 or more citations. The top 100 articles were further stratified by country, institution, and study type.

The authors found that half of the top 100 cited articles were from the United States; 81 of them were original articles. The majority of the top 100 articles were from dermatology programs in the United States, but institutions in the United Kingdom and Germany also made notable contributions.

There were 2 periods of particular note in their analysis. The high numbers of citations from 1985 to 1989 correlated with the elucidation of the immune-mediated pathogenesis of psoriasis at that time. The high number of top citations from 2000 to 2004 correlated with the development of biologic agents in psoriasis therapy.

 

What’s the issue?

It is interesting to see which studies have been most influential in this highly active area of dermatology. What articles have most influenced your approach to psoriasis?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
psoriasis literature, psoriasis therapy, psoriasis pathogenesis
Sections
Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Related Articles

 

 

In the October 2014 issue of the Journal of Clinical and Aesthetic Dermatology (2014;7:10-19), Wu et al published the top 100 most-cited psoriasis articles in clinical dermatologic journals from 1970 to 2012. Given the explosion of literature in this area, I was very excited to rush to find the list online.  

The authors conducted a citation analysis of major clinical dermatologic journals from 1970 to 2012 limited to the subject of psoriasis. They used the search term psoriasis in the Science Citation Index from 1970 to 2012 and included articles that have received 100 or more citations. The top 100 articles were further stratified by country, institution, and study type.

The authors found that half of the top 100 cited articles were from the United States; 81 of them were original articles. The majority of the top 100 articles were from dermatology programs in the United States, but institutions in the United Kingdom and Germany also made notable contributions.

There were 2 periods of particular note in their analysis. The high numbers of citations from 1985 to 1989 correlated with the elucidation of the immune-mediated pathogenesis of psoriasis at that time. The high number of top citations from 2000 to 2004 correlated with the development of biologic agents in psoriasis therapy.

 

What’s the issue?

It is interesting to see which studies have been most influential in this highly active area of dermatology. What articles have most influenced your approach to psoriasis?

We want to know your views! Tell us what you think.

 

 

In the October 2014 issue of the Journal of Clinical and Aesthetic Dermatology (2014;7:10-19), Wu et al published the top 100 most-cited psoriasis articles in clinical dermatologic journals from 1970 to 2012. Given the explosion of literature in this area, I was very excited to rush to find the list online.  

The authors conducted a citation analysis of major clinical dermatologic journals from 1970 to 2012 limited to the subject of psoriasis. They used the search term psoriasis in the Science Citation Index from 1970 to 2012 and included articles that have received 100 or more citations. The top 100 articles were further stratified by country, institution, and study type.

The authors found that half of the top 100 cited articles were from the United States; 81 of them were original articles. The majority of the top 100 articles were from dermatology programs in the United States, but institutions in the United Kingdom and Germany also made notable contributions.

There were 2 periods of particular note in their analysis. The high numbers of citations from 1985 to 1989 correlated with the elucidation of the immune-mediated pathogenesis of psoriasis at that time. The high number of top citations from 2000 to 2004 correlated with the development of biologic agents in psoriasis therapy.

 

What’s the issue?

It is interesting to see which studies have been most influential in this highly active area of dermatology. What articles have most influenced your approach to psoriasis?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
The Top 100
Display Headline
The Top 100
Legacy Keywords
psoriasis literature, psoriasis therapy, psoriasis pathogenesis
Legacy Keywords
psoriasis literature, psoriasis therapy, psoriasis pathogenesis
Sections
Disallow All Ads
Alternative CME

Old Concept, New Drug: Topical Application of Systemic Antineoplastic Agent to Treat Skin Cancer

Article Type
Changed
Display Headline
Old Concept, New Drug: Topical Application of Systemic Antineoplastic Agent to Treat Skin Cancer

In a June 29 article published online in Molecular Carcinogenesis, Fenton et al demonstrated that topical dasatinib treatment of UVB-exposed SKH1 hairless mice reduced the total tumor burden (ie, benign tumors, atypical benign tumors, squamous cell carcinomas) per mouse.

Dasatinib is a tyrosine kinase inhibitor currently used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Its mechanism of action is to block the activity of tyrosine kinases by attaching to their adenosine triphosphate–binding site. It can inhibit the activity of the following tyrosine kinases: Src family kinases (SFK), break point cluster region-Abelson (Bcr-Abl), Ephrin type-A receptor 2 (EphA2), platelet-derived growth factor receptor, and mast/stem cell factor receptor (also called CD117 or c-Kit).

Src family kinases are associated with transformation of cells and progression of cancer. Elevated Src family kinases activity is present in the majority of human carcinomas.

Fyn, a nonreceptor tyrosine kinase, is a member of the Src family kinases. Cell growth, cell migration, and protein kinase B (Akt)–mediated inhibition of apoptosis are influenced by Fyn activity. In addition, Fyn activity is overexpressed in cutaneous squamous cell carcinoma.

In conclusion, dasatinib—an Src family kinases inhibitor—was able to inhibit Fyn activity and thereby reduce UV-induced skin carcinogenesis.

 

What’s the issue?

In 1962, Falkson and Schulz (Br J Dermatol. 1962;74:229-236) noted not only inflammation and subsequent resolution of actinic keratoses after exposure to sunlight in a woman with colon cancer being treated with systemic 5-fluorouracil but also several other patients whose keratoses were seen to disappear during therapy without preceding erythema. Omura and Torre (JAMA. 1969;208:150-151) confirmed these observations in a woman with breast cancer whose actinic keratoses became inflamed after receiving intravenous 5-fluorouracil and subsequently faded. The route of drug administration was modified and 5-fluorouracil was applied topically. Today topical 5-fluorouracil is still used for the treatment of actinic keratoses.

Topical application of nitrogen mustard is used in the treatment of cutaneous T-cell lymphoma. In addition, intralesional administration of systemic antineoplastic agents has been used to treat cutaneous neoplasms: methotrexate for keratoacanthomas and rituximab for primary cutaneous B-cell lymphomas.

The Fenton et al study suggests that topical dasatinib may be a potential therapeutic intervention for the treatment of cutaneous squamous cell carcinoma. The investigators not only demonstrate laboratory data from mouse studies but also provide a potential molecular mechanism for drug-associated tumor suppression. Indeed, dasatinib solution, dasatinib cream, or both may be the next innovative therapy for the suppression of cutaneous squamous cell carcinoma in organ transplant and immunocompromised patients and for the potential management of this skin cancer in immunocompetent individuals. What do you think?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Cohen is from the Division of Dermatology, University of California San Diego.

Dr. Cohen reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
dasatinib, skin cancer treatment, topical therapy for skin cancer, squamous cell carcinoma, skin carcinogenesis
Sections
Author and Disclosure Information

Dr. Cohen is from the Division of Dermatology, University of California San Diego.

Dr. Cohen reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Cohen is from the Division of Dermatology, University of California San Diego.

Dr. Cohen reports no conflicts of interest in relation to this post.

Related Articles

In a June 29 article published online in Molecular Carcinogenesis, Fenton et al demonstrated that topical dasatinib treatment of UVB-exposed SKH1 hairless mice reduced the total tumor burden (ie, benign tumors, atypical benign tumors, squamous cell carcinomas) per mouse.

Dasatinib is a tyrosine kinase inhibitor currently used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Its mechanism of action is to block the activity of tyrosine kinases by attaching to their adenosine triphosphate–binding site. It can inhibit the activity of the following tyrosine kinases: Src family kinases (SFK), break point cluster region-Abelson (Bcr-Abl), Ephrin type-A receptor 2 (EphA2), platelet-derived growth factor receptor, and mast/stem cell factor receptor (also called CD117 or c-Kit).

Src family kinases are associated with transformation of cells and progression of cancer. Elevated Src family kinases activity is present in the majority of human carcinomas.

Fyn, a nonreceptor tyrosine kinase, is a member of the Src family kinases. Cell growth, cell migration, and protein kinase B (Akt)–mediated inhibition of apoptosis are influenced by Fyn activity. In addition, Fyn activity is overexpressed in cutaneous squamous cell carcinoma.

In conclusion, dasatinib—an Src family kinases inhibitor—was able to inhibit Fyn activity and thereby reduce UV-induced skin carcinogenesis.

 

What’s the issue?

In 1962, Falkson and Schulz (Br J Dermatol. 1962;74:229-236) noted not only inflammation and subsequent resolution of actinic keratoses after exposure to sunlight in a woman with colon cancer being treated with systemic 5-fluorouracil but also several other patients whose keratoses were seen to disappear during therapy without preceding erythema. Omura and Torre (JAMA. 1969;208:150-151) confirmed these observations in a woman with breast cancer whose actinic keratoses became inflamed after receiving intravenous 5-fluorouracil and subsequently faded. The route of drug administration was modified and 5-fluorouracil was applied topically. Today topical 5-fluorouracil is still used for the treatment of actinic keratoses.

Topical application of nitrogen mustard is used in the treatment of cutaneous T-cell lymphoma. In addition, intralesional administration of systemic antineoplastic agents has been used to treat cutaneous neoplasms: methotrexate for keratoacanthomas and rituximab for primary cutaneous B-cell lymphomas.

The Fenton et al study suggests that topical dasatinib may be a potential therapeutic intervention for the treatment of cutaneous squamous cell carcinoma. The investigators not only demonstrate laboratory data from mouse studies but also provide a potential molecular mechanism for drug-associated tumor suppression. Indeed, dasatinib solution, dasatinib cream, or both may be the next innovative therapy for the suppression of cutaneous squamous cell carcinoma in organ transplant and immunocompromised patients and for the potential management of this skin cancer in immunocompetent individuals. What do you think?

We want to know your views! Tell us what you think.

In a June 29 article published online in Molecular Carcinogenesis, Fenton et al demonstrated that topical dasatinib treatment of UVB-exposed SKH1 hairless mice reduced the total tumor burden (ie, benign tumors, atypical benign tumors, squamous cell carcinomas) per mouse.

Dasatinib is a tyrosine kinase inhibitor currently used to treat imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Its mechanism of action is to block the activity of tyrosine kinases by attaching to their adenosine triphosphate–binding site. It can inhibit the activity of the following tyrosine kinases: Src family kinases (SFK), break point cluster region-Abelson (Bcr-Abl), Ephrin type-A receptor 2 (EphA2), platelet-derived growth factor receptor, and mast/stem cell factor receptor (also called CD117 or c-Kit).

Src family kinases are associated with transformation of cells and progression of cancer. Elevated Src family kinases activity is present in the majority of human carcinomas.

Fyn, a nonreceptor tyrosine kinase, is a member of the Src family kinases. Cell growth, cell migration, and protein kinase B (Akt)–mediated inhibition of apoptosis are influenced by Fyn activity. In addition, Fyn activity is overexpressed in cutaneous squamous cell carcinoma.

In conclusion, dasatinib—an Src family kinases inhibitor—was able to inhibit Fyn activity and thereby reduce UV-induced skin carcinogenesis.

 

What’s the issue?

In 1962, Falkson and Schulz (Br J Dermatol. 1962;74:229-236) noted not only inflammation and subsequent resolution of actinic keratoses after exposure to sunlight in a woman with colon cancer being treated with systemic 5-fluorouracil but also several other patients whose keratoses were seen to disappear during therapy without preceding erythema. Omura and Torre (JAMA. 1969;208:150-151) confirmed these observations in a woman with breast cancer whose actinic keratoses became inflamed after receiving intravenous 5-fluorouracil and subsequently faded. The route of drug administration was modified and 5-fluorouracil was applied topically. Today topical 5-fluorouracil is still used for the treatment of actinic keratoses.

Topical application of nitrogen mustard is used in the treatment of cutaneous T-cell lymphoma. In addition, intralesional administration of systemic antineoplastic agents has been used to treat cutaneous neoplasms: methotrexate for keratoacanthomas and rituximab for primary cutaneous B-cell lymphomas.

The Fenton et al study suggests that topical dasatinib may be a potential therapeutic intervention for the treatment of cutaneous squamous cell carcinoma. The investigators not only demonstrate laboratory data from mouse studies but also provide a potential molecular mechanism for drug-associated tumor suppression. Indeed, dasatinib solution, dasatinib cream, or both may be the next innovative therapy for the suppression of cutaneous squamous cell carcinoma in organ transplant and immunocompromised patients and for the potential management of this skin cancer in immunocompetent individuals. What do you think?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
Old Concept, New Drug: Topical Application of Systemic Antineoplastic Agent to Treat Skin Cancer
Display Headline
Old Concept, New Drug: Topical Application of Systemic Antineoplastic Agent to Treat Skin Cancer
Legacy Keywords
dasatinib, skin cancer treatment, topical therapy for skin cancer, squamous cell carcinoma, skin carcinogenesis
Legacy Keywords
dasatinib, skin cancer treatment, topical therapy for skin cancer, squamous cell carcinoma, skin carcinogenesis
Sections
Disallow All Ads

Reducing Risks

Article Type
Changed
Display Headline
Reducing Risks

 

 

Psoriasis is associated with multiple comorbidities, including cardiovascular diseases. With the advent of anti-inflammatory therapy, there has been much investigation into whether treatments for psoriasis may reduce the risk for cardiovascular events. In a Journal of the European Academy of Dermatology and Venereology article published online on October 10, Ahlehoff et al examined the rate of cardiovascular events—cardiovascular death, myocardial infarction, and stroke—in patients with severe psoriasis treated with systemic anti-inflammatory drugs.

Individual-level linkage of administrative registries was utilized to perform a longitudinal nationwide cohort study in Denmark. Time-dependent multivariable adjusted Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of cardiovascular events associated with use of biological drugs, methotrexate, cyclosporine, retinoids, and other antipsoriatic therapies (ie, topical treatments, phototherapy, climate therapy).

The investigators included a total of 6902 patients (9662 treatment exposures) with a maximum follow-up of 5 years. Incidence rates per 1000 patient-years for cardiovascular events were highest for retinoids and other therapies (18.95 and 14.63, respectively) followed by methotrexate, cyclosporine, and biological drugs (6.28, 6.08, and 4.16, respectively). Relative to other therapies, methotrexate (HR, 0.53; 95% CI, 0.34-0.83) was associated with reduced risk for the composite end point. A comparable but nonsignificant protective effect was observed with biological drugs (HR, 0.58; 95% CI, 0.30-1.10), whereas no protective effect was apparent with cyclosporine (HR, 1.06; 95% CI, 0.26-4.27) and retinoids (HR, 1.80; 95% CI, 1.03-2.96). Tumor necrosis factor inhibitors (HR, 0.46; 95% CI, 0.22-0.98) were linked to reduced event rates but the IL-12/IL-23 inhibitor ustekinumab (HR, 1.52; 95% CI, 0.47-4.94) was not.

The authors concluded that systemic anti-inflammatory treatment with methotrexate was associated with lower rates of cardiovascular events during long-term follow-up compared to patients treated with other antipsoriatic therapies.

 

What’s the issue?

This study is consistent with other investigations evaluating the cardioprotective benefit of therapies for psoriasis. The cardioprotective benefits of methotrexate and tumor necrosis factor inhibitors have been previously reported. Further investigation will help to elucidate the role of these drugs as well as newer therapies in the reduction of comorbidities. Does this study influence your perception of therapies for psoriasis?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
psoriasis, cardiovascular diseases, comorbidity, myocardial infarction, cardiovascular events, cardiovascular comorbidities, psoriasis treatment
Sections
Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Related Articles

 

 

Psoriasis is associated with multiple comorbidities, including cardiovascular diseases. With the advent of anti-inflammatory therapy, there has been much investigation into whether treatments for psoriasis may reduce the risk for cardiovascular events. In a Journal of the European Academy of Dermatology and Venereology article published online on October 10, Ahlehoff et al examined the rate of cardiovascular events—cardiovascular death, myocardial infarction, and stroke—in patients with severe psoriasis treated with systemic anti-inflammatory drugs.

Individual-level linkage of administrative registries was utilized to perform a longitudinal nationwide cohort study in Denmark. Time-dependent multivariable adjusted Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of cardiovascular events associated with use of biological drugs, methotrexate, cyclosporine, retinoids, and other antipsoriatic therapies (ie, topical treatments, phototherapy, climate therapy).

The investigators included a total of 6902 patients (9662 treatment exposures) with a maximum follow-up of 5 years. Incidence rates per 1000 patient-years for cardiovascular events were highest for retinoids and other therapies (18.95 and 14.63, respectively) followed by methotrexate, cyclosporine, and biological drugs (6.28, 6.08, and 4.16, respectively). Relative to other therapies, methotrexate (HR, 0.53; 95% CI, 0.34-0.83) was associated with reduced risk for the composite end point. A comparable but nonsignificant protective effect was observed with biological drugs (HR, 0.58; 95% CI, 0.30-1.10), whereas no protective effect was apparent with cyclosporine (HR, 1.06; 95% CI, 0.26-4.27) and retinoids (HR, 1.80; 95% CI, 1.03-2.96). Tumor necrosis factor inhibitors (HR, 0.46; 95% CI, 0.22-0.98) were linked to reduced event rates but the IL-12/IL-23 inhibitor ustekinumab (HR, 1.52; 95% CI, 0.47-4.94) was not.

The authors concluded that systemic anti-inflammatory treatment with methotrexate was associated with lower rates of cardiovascular events during long-term follow-up compared to patients treated with other antipsoriatic therapies.

 

What’s the issue?

This study is consistent with other investigations evaluating the cardioprotective benefit of therapies for psoriasis. The cardioprotective benefits of methotrexate and tumor necrosis factor inhibitors have been previously reported. Further investigation will help to elucidate the role of these drugs as well as newer therapies in the reduction of comorbidities. Does this study influence your perception of therapies for psoriasis?

We want to know your views! Tell us what you think.

 

 

Psoriasis is associated with multiple comorbidities, including cardiovascular diseases. With the advent of anti-inflammatory therapy, there has been much investigation into whether treatments for psoriasis may reduce the risk for cardiovascular events. In a Journal of the European Academy of Dermatology and Venereology article published online on October 10, Ahlehoff et al examined the rate of cardiovascular events—cardiovascular death, myocardial infarction, and stroke—in patients with severe psoriasis treated with systemic anti-inflammatory drugs.

Individual-level linkage of administrative registries was utilized to perform a longitudinal nationwide cohort study in Denmark. Time-dependent multivariable adjusted Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of cardiovascular events associated with use of biological drugs, methotrexate, cyclosporine, retinoids, and other antipsoriatic therapies (ie, topical treatments, phototherapy, climate therapy).

The investigators included a total of 6902 patients (9662 treatment exposures) with a maximum follow-up of 5 years. Incidence rates per 1000 patient-years for cardiovascular events were highest for retinoids and other therapies (18.95 and 14.63, respectively) followed by methotrexate, cyclosporine, and biological drugs (6.28, 6.08, and 4.16, respectively). Relative to other therapies, methotrexate (HR, 0.53; 95% CI, 0.34-0.83) was associated with reduced risk for the composite end point. A comparable but nonsignificant protective effect was observed with biological drugs (HR, 0.58; 95% CI, 0.30-1.10), whereas no protective effect was apparent with cyclosporine (HR, 1.06; 95% CI, 0.26-4.27) and retinoids (HR, 1.80; 95% CI, 1.03-2.96). Tumor necrosis factor inhibitors (HR, 0.46; 95% CI, 0.22-0.98) were linked to reduced event rates but the IL-12/IL-23 inhibitor ustekinumab (HR, 1.52; 95% CI, 0.47-4.94) was not.

The authors concluded that systemic anti-inflammatory treatment with methotrexate was associated with lower rates of cardiovascular events during long-term follow-up compared to patients treated with other antipsoriatic therapies.

 

What’s the issue?

This study is consistent with other investigations evaluating the cardioprotective benefit of therapies for psoriasis. The cardioprotective benefits of methotrexate and tumor necrosis factor inhibitors have been previously reported. Further investigation will help to elucidate the role of these drugs as well as newer therapies in the reduction of comorbidities. Does this study influence your perception of therapies for psoriasis?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
Reducing Risks
Display Headline
Reducing Risks
Legacy Keywords
psoriasis, cardiovascular diseases, comorbidity, myocardial infarction, cardiovascular events, cardiovascular comorbidities, psoriasis treatment
Legacy Keywords
psoriasis, cardiovascular diseases, comorbidity, myocardial infarction, cardiovascular events, cardiovascular comorbidities, psoriasis treatment
Sections
Disallow All Ads
Alternative CME

At Last? Apremilast

Article Type
Changed
Display Headline
At Last? Apremilast

 

 

In late September 2014, the US Food and Drug Administration approved the medication apremilast for treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It was previously approved for psoriatic arthritis in March 2014. Its mechanism includes selective inhibition of phosphodiesterase 4, resulting in increased intracellular cyclic adenosine monophosphate levels, indirectly mediating production of inflammatory mediators in many cell types, namely decreasing tumor necrosis factor α and IL-23 and increasing IL-10. Orally dosed at 30 mg twice daily, safety and efficacy was determined via 2 multicenter, randomized, double-blind, placebo-controlled trials—ESTEEM 1 and ESTEEM 2 (N=1257)—that highlighted a PASI-75 (psoriasis area severity index) in 30% of patients in the first 4 months and up to 88% of patients with PASI-75 in the first year (J Am Acad Dermatol. 2014;70(suppl 1):AB164). Additionally, according to results presented at a recent European Academy of Dermatology and Venereology meeting in early October 2014, pruritus and difficult areas such as the scalp, palmoplantar area, and nails showed significant improvement at week 16 (P<.0001). The most common side effects were diarrhea, nausea, upper respiratory infection, and headache, which occurred most often in the first 2 weeks of therapy. The medication does not require routine laboratory monitoring; however, because weight loss is possible, it is recommended that weight should be periodically checked. There are no contraindications aside from hypersensitivity to the drug itself, and caution should be taken in patients with unstable depression, suicidal ideation, or severe renal impairment. It is pregnancy category C.

 

What’s the issue?

Because it is administered orally; is dually indicated for plaque psoriasis and psoriatic arthritis; and does not require laboratory monitoring, alcohol consumption restrictions, category X classification, or immunosuppressive infection or cancer risk, the window-shopping appeal of this drug seems attractive compared to the veteran and contemporary pharmaceutical army of psoriasis therapy. However, based on the ESTEEM studies, meager apremilast PASI scores are not blowing us away like those of biologic medications. At a time when the evolution of medications for psoriasis seems like a revolving door for new products highlighting new mechanisms in new pathways in even newer cells in relationship to inflammation, how will this drug fit in?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
psoriasis, psoriatic arthritis, apremilast, Otezla, FDA, phosphodiesterase inhibitor
Sections
Author and Disclosure Information

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.

Dr. Rosamilia reports no conflicts of interest in relation to this post.

Related Articles

 

 

In late September 2014, the US Food and Drug Administration approved the medication apremilast for treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It was previously approved for psoriatic arthritis in March 2014. Its mechanism includes selective inhibition of phosphodiesterase 4, resulting in increased intracellular cyclic adenosine monophosphate levels, indirectly mediating production of inflammatory mediators in many cell types, namely decreasing tumor necrosis factor α and IL-23 and increasing IL-10. Orally dosed at 30 mg twice daily, safety and efficacy was determined via 2 multicenter, randomized, double-blind, placebo-controlled trials—ESTEEM 1 and ESTEEM 2 (N=1257)—that highlighted a PASI-75 (psoriasis area severity index) in 30% of patients in the first 4 months and up to 88% of patients with PASI-75 in the first year (J Am Acad Dermatol. 2014;70(suppl 1):AB164). Additionally, according to results presented at a recent European Academy of Dermatology and Venereology meeting in early October 2014, pruritus and difficult areas such as the scalp, palmoplantar area, and nails showed significant improvement at week 16 (P<.0001). The most common side effects were diarrhea, nausea, upper respiratory infection, and headache, which occurred most often in the first 2 weeks of therapy. The medication does not require routine laboratory monitoring; however, because weight loss is possible, it is recommended that weight should be periodically checked. There are no contraindications aside from hypersensitivity to the drug itself, and caution should be taken in patients with unstable depression, suicidal ideation, or severe renal impairment. It is pregnancy category C.

 

What’s the issue?

Because it is administered orally; is dually indicated for plaque psoriasis and psoriatic arthritis; and does not require laboratory monitoring, alcohol consumption restrictions, category X classification, or immunosuppressive infection or cancer risk, the window-shopping appeal of this drug seems attractive compared to the veteran and contemporary pharmaceutical army of psoriasis therapy. However, based on the ESTEEM studies, meager apremilast PASI scores are not blowing us away like those of biologic medications. At a time when the evolution of medications for psoriasis seems like a revolving door for new products highlighting new mechanisms in new pathways in even newer cells in relationship to inflammation, how will this drug fit in?

We want to know your views! Tell us what you think.

 

 

In late September 2014, the US Food and Drug Administration approved the medication apremilast for treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It was previously approved for psoriatic arthritis in March 2014. Its mechanism includes selective inhibition of phosphodiesterase 4, resulting in increased intracellular cyclic adenosine monophosphate levels, indirectly mediating production of inflammatory mediators in many cell types, namely decreasing tumor necrosis factor α and IL-23 and increasing IL-10. Orally dosed at 30 mg twice daily, safety and efficacy was determined via 2 multicenter, randomized, double-blind, placebo-controlled trials—ESTEEM 1 and ESTEEM 2 (N=1257)—that highlighted a PASI-75 (psoriasis area severity index) in 30% of patients in the first 4 months and up to 88% of patients with PASI-75 in the first year (J Am Acad Dermatol. 2014;70(suppl 1):AB164). Additionally, according to results presented at a recent European Academy of Dermatology and Venereology meeting in early October 2014, pruritus and difficult areas such as the scalp, palmoplantar area, and nails showed significant improvement at week 16 (P<.0001). The most common side effects were diarrhea, nausea, upper respiratory infection, and headache, which occurred most often in the first 2 weeks of therapy. The medication does not require routine laboratory monitoring; however, because weight loss is possible, it is recommended that weight should be periodically checked. There are no contraindications aside from hypersensitivity to the drug itself, and caution should be taken in patients with unstable depression, suicidal ideation, or severe renal impairment. It is pregnancy category C.

 

What’s the issue?

Because it is administered orally; is dually indicated for plaque psoriasis and psoriatic arthritis; and does not require laboratory monitoring, alcohol consumption restrictions, category X classification, or immunosuppressive infection or cancer risk, the window-shopping appeal of this drug seems attractive compared to the veteran and contemporary pharmaceutical army of psoriasis therapy. However, based on the ESTEEM studies, meager apremilast PASI scores are not blowing us away like those of biologic medications. At a time when the evolution of medications for psoriasis seems like a revolving door for new products highlighting new mechanisms in new pathways in even newer cells in relationship to inflammation, how will this drug fit in?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
At Last? Apremilast
Display Headline
At Last? Apremilast
Legacy Keywords
psoriasis, psoriatic arthritis, apremilast, Otezla, FDA, phosphodiesterase inhibitor
Legacy Keywords
psoriasis, psoriatic arthritis, apremilast, Otezla, FDA, phosphodiesterase inhibitor
Sections
Disallow All Ads
Alternative CME

Dermabrasion Versus Tretinoin: The Stretch Mark Showdown

Article Type
Changed
Display Headline
Dermabrasion Versus Tretinoin: The Stretch Mark Showdown

Striae cutis distensae, colloquially known as stretch marks, are extremely common and are difficult to treat. Hexsel et al (Dermatol Surg. 2014;40:537-544) published a randomized pilot study to evaluate the efficacy of superficial dermabrasion versus topical tretinoin in the treatment of striae cutis distensae. Thirty-two women were enrolled and all had early (<6 months) striae rubra measuring up to a maximum of 5 mm in length. Exclusion criteria included any striae alba in the area. Two treatment groups were randomized: one received 16 weekly sessions of localized superficial dermabrasion, and the other group applied tretinoin cream 0.05% daily for 16 weeks. All participants were assessed at 4, 8, 12, and 16 weeks. A 3-mm diamond tip rotating at 10,000 revolutions per minute was used for the dermabrasion. The clinical end point of the superficial dermabrasion was no pain or bleeding. Tretinoin was applied once daily at night. The 5-point global aesthetic improvement scale was used to assess patient improvement and biopsies were done in willing participants.

Both groups experienced significant reduction in the width and length of the striae cutis distensae from baseline (P<.05). No differences were seen between the 2 groups, and the global aesthetic improvement scale score did not differ between the 2 groups. Fourteen participants had adverse events including pruritus, erythema, burning, scaling, crusts, swelling, and papules. There was no statistically significant difference in adverse events between treatments; however, the tretinoin group did experience more scaling, pruritus, and erythema. Eight biopsies were done in the dermabrasion group and 1 was done in the tretinoin group. The dermabrasion group showed histologic evidence of epidermal and dermal improvement with a decrease in elastolysis, collagen fragmentation, and epidermal atrophy, as well as an increase in neocollagenesis.

 

What’s the issue?

Striae cutis distensae is a common and often distressing skin condition. It is well known that treating early striae rubra may be more efficacious than treating later striae alba. Many methods have been employed to treat striae rubra including lasers and creams. This study places superficial dermabrasion against tretinoin in a prospective manner. Although both treatment groups saw improvement, the tretinoin group was noted to experience more scaling, pruritus, and erythema, which can affect treatment adherence and compliance. Dermabrasion was shown to have beneficial effects via histologic examination, not just on the appearance of the striae but also on the skin structures. Dermabrasion can be a suitable option for patients who cannot pursue more costly laser treatments or expensive tretinoin prescriptions. When a patient presents with striae, what is your go-to treatment?

We want to know your views! Tell us what you think.

 

Reader Comment
How do you rationalize that dermabrasion is less expensive than tretinoin? Patients can purchase it online if their insurance won't cover it.

--Deborah Ohlhausen, MD

 

Author Comment

This article points out that dermabrasion can be a suitable treatment option. Tretinoin can be expensive if not covered by insurance. Online purchase is not recommended due to the question of safety and efficacy. Therefore, dermabrasion may be a suitable alternative as pointed out by this study.

--Anthony M. Rossi, MD

Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan-Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
striae distensae, striae cutis distensae, tretinoin, dermabrasion, stretch marks treatment, striae treatment
Sections
Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan-Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Rossi is an Assistant Attending at Memorial Sloan-Kettering Cancer Center, New York, New York.

Dr. Rossi reports no conflicts of interest in relation to this post.

Related Articles

Striae cutis distensae, colloquially known as stretch marks, are extremely common and are difficult to treat. Hexsel et al (Dermatol Surg. 2014;40:537-544) published a randomized pilot study to evaluate the efficacy of superficial dermabrasion versus topical tretinoin in the treatment of striae cutis distensae. Thirty-two women were enrolled and all had early (<6 months) striae rubra measuring up to a maximum of 5 mm in length. Exclusion criteria included any striae alba in the area. Two treatment groups were randomized: one received 16 weekly sessions of localized superficial dermabrasion, and the other group applied tretinoin cream 0.05% daily for 16 weeks. All participants were assessed at 4, 8, 12, and 16 weeks. A 3-mm diamond tip rotating at 10,000 revolutions per minute was used for the dermabrasion. The clinical end point of the superficial dermabrasion was no pain or bleeding. Tretinoin was applied once daily at night. The 5-point global aesthetic improvement scale was used to assess patient improvement and biopsies were done in willing participants.

Both groups experienced significant reduction in the width and length of the striae cutis distensae from baseline (P<.05). No differences were seen between the 2 groups, and the global aesthetic improvement scale score did not differ between the 2 groups. Fourteen participants had adverse events including pruritus, erythema, burning, scaling, crusts, swelling, and papules. There was no statistically significant difference in adverse events between treatments; however, the tretinoin group did experience more scaling, pruritus, and erythema. Eight biopsies were done in the dermabrasion group and 1 was done in the tretinoin group. The dermabrasion group showed histologic evidence of epidermal and dermal improvement with a decrease in elastolysis, collagen fragmentation, and epidermal atrophy, as well as an increase in neocollagenesis.

 

What’s the issue?

Striae cutis distensae is a common and often distressing skin condition. It is well known that treating early striae rubra may be more efficacious than treating later striae alba. Many methods have been employed to treat striae rubra including lasers and creams. This study places superficial dermabrasion against tretinoin in a prospective manner. Although both treatment groups saw improvement, the tretinoin group was noted to experience more scaling, pruritus, and erythema, which can affect treatment adherence and compliance. Dermabrasion was shown to have beneficial effects via histologic examination, not just on the appearance of the striae but also on the skin structures. Dermabrasion can be a suitable option for patients who cannot pursue more costly laser treatments or expensive tretinoin prescriptions. When a patient presents with striae, what is your go-to treatment?

We want to know your views! Tell us what you think.

 

Reader Comment
How do you rationalize that dermabrasion is less expensive than tretinoin? Patients can purchase it online if their insurance won't cover it.

--Deborah Ohlhausen, MD

 

Author Comment

This article points out that dermabrasion can be a suitable treatment option. Tretinoin can be expensive if not covered by insurance. Online purchase is not recommended due to the question of safety and efficacy. Therefore, dermabrasion may be a suitable alternative as pointed out by this study.

--Anthony M. Rossi, MD

Striae cutis distensae, colloquially known as stretch marks, are extremely common and are difficult to treat. Hexsel et al (Dermatol Surg. 2014;40:537-544) published a randomized pilot study to evaluate the efficacy of superficial dermabrasion versus topical tretinoin in the treatment of striae cutis distensae. Thirty-two women were enrolled and all had early (<6 months) striae rubra measuring up to a maximum of 5 mm in length. Exclusion criteria included any striae alba in the area. Two treatment groups were randomized: one received 16 weekly sessions of localized superficial dermabrasion, and the other group applied tretinoin cream 0.05% daily for 16 weeks. All participants were assessed at 4, 8, 12, and 16 weeks. A 3-mm diamond tip rotating at 10,000 revolutions per minute was used for the dermabrasion. The clinical end point of the superficial dermabrasion was no pain or bleeding. Tretinoin was applied once daily at night. The 5-point global aesthetic improvement scale was used to assess patient improvement and biopsies were done in willing participants.

Both groups experienced significant reduction in the width and length of the striae cutis distensae from baseline (P<.05). No differences were seen between the 2 groups, and the global aesthetic improvement scale score did not differ between the 2 groups. Fourteen participants had adverse events including pruritus, erythema, burning, scaling, crusts, swelling, and papules. There was no statistically significant difference in adverse events between treatments; however, the tretinoin group did experience more scaling, pruritus, and erythema. Eight biopsies were done in the dermabrasion group and 1 was done in the tretinoin group. The dermabrasion group showed histologic evidence of epidermal and dermal improvement with a decrease in elastolysis, collagen fragmentation, and epidermal atrophy, as well as an increase in neocollagenesis.

 

What’s the issue?

Striae cutis distensae is a common and often distressing skin condition. It is well known that treating early striae rubra may be more efficacious than treating later striae alba. Many methods have been employed to treat striae rubra including lasers and creams. This study places superficial dermabrasion against tretinoin in a prospective manner. Although both treatment groups saw improvement, the tretinoin group was noted to experience more scaling, pruritus, and erythema, which can affect treatment adherence and compliance. Dermabrasion was shown to have beneficial effects via histologic examination, not just on the appearance of the striae but also on the skin structures. Dermabrasion can be a suitable option for patients who cannot pursue more costly laser treatments or expensive tretinoin prescriptions. When a patient presents with striae, what is your go-to treatment?

We want to know your views! Tell us what you think.

 

Reader Comment
How do you rationalize that dermabrasion is less expensive than tretinoin? Patients can purchase it online if their insurance won't cover it.

--Deborah Ohlhausen, MD

 

Author Comment

This article points out that dermabrasion can be a suitable treatment option. Tretinoin can be expensive if not covered by insurance. Online purchase is not recommended due to the question of safety and efficacy. Therefore, dermabrasion may be a suitable alternative as pointed out by this study.

--Anthony M. Rossi, MD

Publications
Publications
Topics
Article Type
Display Headline
Dermabrasion Versus Tretinoin: The Stretch Mark Showdown
Display Headline
Dermabrasion Versus Tretinoin: The Stretch Mark Showdown
Legacy Keywords
striae distensae, striae cutis distensae, tretinoin, dermabrasion, stretch marks treatment, striae treatment
Legacy Keywords
striae distensae, striae cutis distensae, tretinoin, dermabrasion, stretch marks treatment, striae treatment
Sections
Disallow All Ads
Alternative CME

Psoriasis for Seniors

Article Type
Changed
Display Headline
Psoriasis for Seniors

 

 

We are always conscious of the use of systemic medications in older patients, as they may have the potential for more toxicity. For dermatologists, use of systemic medications in psoriasis represents a large share of our total use. Theoretically, we are concerned that older patients may be more likely to develop serious infections and malignancies. Older psoriasis patients also represent a growing demographic, and they are underrepresented in clinical trials.

In an article published online on September 3, 2014, in the Journal of the European Academy of Dermatology and Venereology, Medina et al performed an analysis to evaluate the safety of systemic psoriasis therapy in patients older than 65 years compared to younger patients. Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were divided into 2 categories: elderly (≥65 years) and younger patients (<65 years). Rates of adverse events (AEs) were described by severity and type. The risks were compared in both groups, taking into account exposure to classic or biologic drugs using Cox regression.

In the overall study population, 175 (9.8%) of 1793 patients were elderly. The authors found that overall risk for AEs was not higher in elderly patients; the drug group–adjusted hazard ratio (HR) was 1.09 (95% confidence interval [CI], 0.93-1.3). However, serious AEs were more common in older patients, with a drug group–adjusted HR of 3.2 (95% CI, 2.0-5.1). Age-adjusted HR of all AEs was lower for patients exposed to biologics compared to classic drugs in the whole sample (HR, 0.7 [95% CI, 0.6-0.7]). Age did not seem to modify the effect of therapy (biologic vs classic) in the risk for AEs (likelihood ratio test for interaction: P=.12 for all AEs; P=.09 for serious AEs).

The authors concluded that serious AEs were more common in elderly patients. They argued, however, that these serious AEs might be related to other factors associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk for AEs in the whole group. There were no differences in this association between young and old. These results are reassuring, though uncontrolled confounding could not be excluded as an explanation for these findings. The power of the study to detect differences was low.

 

What’s the issue?

The results indicate that overall there is no increase in AEs in older patients. More data will need to be evaluated to see if the incidence of serious AEs is due to medication use or endogenous health factors. How do you approach the use of systemic medications in older patients?

We want to know your views! Tell us what you think.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Publications
Topics
Legacy Keywords
older patients, elderly patients with psoriasis, systemic medications for psoriasis, adverse events
Sections
Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Author and Disclosure Information

Dr. Weinberg is from the Icahn School of Medicine at Mount Sinai, New York, New York.

Dr. Weinberg reports no conflicts of interest in relation to this post.

Related Articles

 

 

We are always conscious of the use of systemic medications in older patients, as they may have the potential for more toxicity. For dermatologists, use of systemic medications in psoriasis represents a large share of our total use. Theoretically, we are concerned that older patients may be more likely to develop serious infections and malignancies. Older psoriasis patients also represent a growing demographic, and they are underrepresented in clinical trials.

In an article published online on September 3, 2014, in the Journal of the European Academy of Dermatology and Venereology, Medina et al performed an analysis to evaluate the safety of systemic psoriasis therapy in patients older than 65 years compared to younger patients. Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were divided into 2 categories: elderly (≥65 years) and younger patients (<65 years). Rates of adverse events (AEs) were described by severity and type. The risks were compared in both groups, taking into account exposure to classic or biologic drugs using Cox regression.

In the overall study population, 175 (9.8%) of 1793 patients were elderly. The authors found that overall risk for AEs was not higher in elderly patients; the drug group–adjusted hazard ratio (HR) was 1.09 (95% confidence interval [CI], 0.93-1.3). However, serious AEs were more common in older patients, with a drug group–adjusted HR of 3.2 (95% CI, 2.0-5.1). Age-adjusted HR of all AEs was lower for patients exposed to biologics compared to classic drugs in the whole sample (HR, 0.7 [95% CI, 0.6-0.7]). Age did not seem to modify the effect of therapy (biologic vs classic) in the risk for AEs (likelihood ratio test for interaction: P=.12 for all AEs; P=.09 for serious AEs).

The authors concluded that serious AEs were more common in elderly patients. They argued, however, that these serious AEs might be related to other factors associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk for AEs in the whole group. There were no differences in this association between young and old. These results are reassuring, though uncontrolled confounding could not be excluded as an explanation for these findings. The power of the study to detect differences was low.

 

What’s the issue?

The results indicate that overall there is no increase in AEs in older patients. More data will need to be evaluated to see if the incidence of serious AEs is due to medication use or endogenous health factors. How do you approach the use of systemic medications in older patients?

We want to know your views! Tell us what you think.

 

 

We are always conscious of the use of systemic medications in older patients, as they may have the potential for more toxicity. For dermatologists, use of systemic medications in psoriasis represents a large share of our total use. Theoretically, we are concerned that older patients may be more likely to develop serious infections and malignancies. Older psoriasis patients also represent a growing demographic, and they are underrepresented in clinical trials.

In an article published online on September 3, 2014, in the Journal of the European Academy of Dermatology and Venereology, Medina et al performed an analysis to evaluate the safety of systemic psoriasis therapy in patients older than 65 years compared to younger patients. Patients registered in Biobadaderm, a Spanish national registry of psoriasis patients treated with systemic therapy, were divided into 2 categories: elderly (≥65 years) and younger patients (<65 years). Rates of adverse events (AEs) were described by severity and type. The risks were compared in both groups, taking into account exposure to classic or biologic drugs using Cox regression.

In the overall study population, 175 (9.8%) of 1793 patients were elderly. The authors found that overall risk for AEs was not higher in elderly patients; the drug group–adjusted hazard ratio (HR) was 1.09 (95% confidence interval [CI], 0.93-1.3). However, serious AEs were more common in older patients, with a drug group–adjusted HR of 3.2 (95% CI, 2.0-5.1). Age-adjusted HR of all AEs was lower for patients exposed to biologics compared to classic drugs in the whole sample (HR, 0.7 [95% CI, 0.6-0.7]). Age did not seem to modify the effect of therapy (biologic vs classic) in the risk for AEs (likelihood ratio test for interaction: P=.12 for all AEs; P=.09 for serious AEs).

The authors concluded that serious AEs were more common in elderly patients. They argued, however, that these serious AEs might be related to other factors associated with this age group and not due to the treatment itself. Use of biologics was associated with lower risk for AEs in the whole group. There were no differences in this association between young and old. These results are reassuring, though uncontrolled confounding could not be excluded as an explanation for these findings. The power of the study to detect differences was low.

 

What’s the issue?

The results indicate that overall there is no increase in AEs in older patients. More data will need to be evaluated to see if the incidence of serious AEs is due to medication use or endogenous health factors. How do you approach the use of systemic medications in older patients?

We want to know your views! Tell us what you think.

Publications
Publications
Topics
Article Type
Display Headline
Psoriasis for Seniors
Display Headline
Psoriasis for Seniors
Legacy Keywords
older patients, elderly patients with psoriasis, systemic medications for psoriasis, adverse events
Legacy Keywords
older patients, elderly patients with psoriasis, systemic medications for psoriasis, adverse events
Sections
Disallow All Ads
Alternative CME

Patient Experience Data Are Outcomes

Article Type
Changed
Display Headline
Patient Experience Data Are Outcomes

From Press Ganey Associates, Inc., Wakefield, MA, and Harvard Medical School and Harvard School of Public Health, Boston, MA.

In fits and starts, but with increasing certainty, health care is changing its organizational focus from the activities of clinicians to meeting the needs of patients. That progress has been slowed and complicated, however, by lack of a performance framework that captures the extent to which patients’ needs are being met. In the absence of such data, “quality” has often been described in terms of the reliability of providers in complying with evidence-based guidelines.

Provider reliability is important, of course, but no substitute for the measurement and improvement of actual patient outcomes. After all, health care exists not to grade providers but to help patients. But clarity on that focus raises some important questions that we have not often discussed in the past.

What exactly are we trying to accomplish in health care? What is the goal? How can we tell how we are doing?

The answers cannot be found solely through measurement of “hard” clinical outcomes, such as death and disability. Yes, these are the most important focuses for improvement in health care, but we cannot deliver immortality, and we often can only delay complications of chronic disease. There is something else that our patients seek from health care, and it can only be measured by asking them directly.

 

Measuring "Peace of Mind"

That “something else” was described by one of my colleagues as “peace of mind that things are as good as they can be, given the cards that we have been dealt.” That may not be the most compact term in health policy, but I have yet to come up with something more concise— and it captures something immediately recognizable as important to anyone who has ever taken care of a patient with a serious disease, or spoken to that patient’s family. Of course, we should do our best to help patients live as long as possible, and of course we should optimize their health and relieve symptoms at every step of the way.

But there are other things that influence the degree of suffering that patients endure along that way, like hope, trust, anxiety, fear, and confusion. They are often considered part of the “art of medicine,” but I think we call them “art” because we are nervous about approaching them with discipline and rigor. In fact, these things can be measured, and managed—and the organizations that improve them are often rewarded with greater market share and professional pride.

Some of my clinician-colleagues do not immediately think of patients’ “peace of mind” as an important outcome, but when their family members or friends have medical problems, this issue immediately comes to the foreground. These clinicians do everything in their power to ensure that their special patients do not have to endure long delays or uncertainty about what is going to happen next, or reconcile conflicting advice, or wait for phone calls that will come…well, sometime soon. We know such experiences are part of what is often called the “disutility of care,” but when they happen to our intimates, we recognize it as something closer to torment.

The bad news is that the challenge of giving patients coordinated care gets harder every year, as medical progress introduces increasing complexity to health care. The good news is that we are in fact getting better at coordinating care every year, because we increasingly recognize the importance of the challenge, and are responding.

Data Collection Advances

One important first step in managing the coordination of care is measuring it. After all, only patients themselves can judge how adequately their needs have been met. And, until recently, the perspectives of patients could only be surmised, and clinicians were expected to improve their “bedside manners” on a case-by-case basis.

But that time has passed. Today, advances in health information systems and in communications technology allow data to be collected from patients at low costs; and for patients to be followed over time so that their outcomes can be measured, analyzed, and improved. Patients can be segmented into groups with similar shared needs, so that teams can be organized to meet those needs. Some of these needs are clearly clinical (eg, control of pain from diseases or treatments), while others are not directly related to patients’ medical problems but  are instead driven by how well health care providers work together.

Evolution of the health care marketplace has made improvement of value for those patient segments a strategic imperative. Provider organizations have to meet the needs of patients if they are to maintain or increase their market share—and, not coincidentally, these organizations are discovering that measurement and improvement of patient experience is an important strategic priority.

In this context, innovations are rapidly being adopted in 4 areas:

  1.  The data that are being collected—Data that reflect how well patients’ needs are being met (ie, actual outcomes) have taken center stage, while data on amenities (eg, food and parking) are increasingly peripheral.
  2. How the data are being collected—Paper and telephone surveys are been supplemented or replaced by electronic methods. Increasingly, health care organizations are seeking email or other electronic ways of communicating with their patients. The reliability of collecting data via older methods is increasingly problematic, and electronic data collection reach patients faster and more efficiently. On average, respondents to electronic surveys are slightly younger than respondents to paper surveys, but the goal of measuring patient experience is to drive improvement; thus, more data is essential (see below).
  3. How much data are collected—The clear trend is away from seeking data from small samples of patients to meet some regulatory requirement, and toward seeking data from large samples of patients (ideally, giving all patients a chance to provide information). Larger amounts of data are needed to analyze data at the levels where true accountability lies, and true improvement can occur, such as the individual clinician’s performance.
  4. How the data are being used—A growing number of organizations are taking bold steps to increase accountability for improving patient experience, up to and including public reporting at an individual physician level. Many organizations are placing a modest financial incentive on improvement, while others use internal peer pressure as their approach. For example, physicians may undergo performance reviews annually at which their patient experience data as well as other performance metrics are discussed. Or organizations may share data internally without blinding, so that clinicians’ colleagues can see the ratings and comments made by patients.

Some of the most dramatic improvements have been made by organizations that have adopted the approach pioneered by the University of Utah Health System, which began sharing all patient ratings and comments on the internet in December 2012. Although Utah’s physicians were of course leery of the risks involved, they have found that the vast majority of patient comments were in fact laudatory—patients want to believe that clinicians are doing a good job, and have a low threshold for praising them. And the small percentage of criticisms from patients have proved powerful drivers of improvement. As a result, Utah and other organizations who are pursuing the transparency approach have seen improvement in patient experience far beyond what one could ever expect using financial incentives.

Summary

In sum, measurement of patient experience is no longer focused upon amenities such as food and parking based on responses from a few hundred patients. Instead, the field is about capturing important outcomes from as many patients as possible, so that teams and individual clinicians can improve their actual patient care. The strategic imperative to measure and manage these outcomes has never been greater; it is the antidote to a major side effect of medical progress, which is the chaos that characterizes modern health care. By asking patients about how their care is really going, I am certain we will respond and improve.

 

Corresponding author: Thomas H. Lee, MD, [email protected]. Dr. Lee is Chief Medical Officer for Press Ganey Associates, Inc.

Issue
Journal of Clinical Outcomes Management - OCTOBER 2014, VOL. 21, NO. 10
Publications
Sections

From Press Ganey Associates, Inc., Wakefield, MA, and Harvard Medical School and Harvard School of Public Health, Boston, MA.

In fits and starts, but with increasing certainty, health care is changing its organizational focus from the activities of clinicians to meeting the needs of patients. That progress has been slowed and complicated, however, by lack of a performance framework that captures the extent to which patients’ needs are being met. In the absence of such data, “quality” has often been described in terms of the reliability of providers in complying with evidence-based guidelines.

Provider reliability is important, of course, but no substitute for the measurement and improvement of actual patient outcomes. After all, health care exists not to grade providers but to help patients. But clarity on that focus raises some important questions that we have not often discussed in the past.

What exactly are we trying to accomplish in health care? What is the goal? How can we tell how we are doing?

The answers cannot be found solely through measurement of “hard” clinical outcomes, such as death and disability. Yes, these are the most important focuses for improvement in health care, but we cannot deliver immortality, and we often can only delay complications of chronic disease. There is something else that our patients seek from health care, and it can only be measured by asking them directly.

 

Measuring "Peace of Mind"

That “something else” was described by one of my colleagues as “peace of mind that things are as good as they can be, given the cards that we have been dealt.” That may not be the most compact term in health policy, but I have yet to come up with something more concise— and it captures something immediately recognizable as important to anyone who has ever taken care of a patient with a serious disease, or spoken to that patient’s family. Of course, we should do our best to help patients live as long as possible, and of course we should optimize their health and relieve symptoms at every step of the way.

But there are other things that influence the degree of suffering that patients endure along that way, like hope, trust, anxiety, fear, and confusion. They are often considered part of the “art of medicine,” but I think we call them “art” because we are nervous about approaching them with discipline and rigor. In fact, these things can be measured, and managed—and the organizations that improve them are often rewarded with greater market share and professional pride.

Some of my clinician-colleagues do not immediately think of patients’ “peace of mind” as an important outcome, but when their family members or friends have medical problems, this issue immediately comes to the foreground. These clinicians do everything in their power to ensure that their special patients do not have to endure long delays or uncertainty about what is going to happen next, or reconcile conflicting advice, or wait for phone calls that will come…well, sometime soon. We know such experiences are part of what is often called the “disutility of care,” but when they happen to our intimates, we recognize it as something closer to torment.

The bad news is that the challenge of giving patients coordinated care gets harder every year, as medical progress introduces increasing complexity to health care. The good news is that we are in fact getting better at coordinating care every year, because we increasingly recognize the importance of the challenge, and are responding.

Data Collection Advances

One important first step in managing the coordination of care is measuring it. After all, only patients themselves can judge how adequately their needs have been met. And, until recently, the perspectives of patients could only be surmised, and clinicians were expected to improve their “bedside manners” on a case-by-case basis.

But that time has passed. Today, advances in health information systems and in communications technology allow data to be collected from patients at low costs; and for patients to be followed over time so that their outcomes can be measured, analyzed, and improved. Patients can be segmented into groups with similar shared needs, so that teams can be organized to meet those needs. Some of these needs are clearly clinical (eg, control of pain from diseases or treatments), while others are not directly related to patients’ medical problems but  are instead driven by how well health care providers work together.

Evolution of the health care marketplace has made improvement of value for those patient segments a strategic imperative. Provider organizations have to meet the needs of patients if they are to maintain or increase their market share—and, not coincidentally, these organizations are discovering that measurement and improvement of patient experience is an important strategic priority.

In this context, innovations are rapidly being adopted in 4 areas:

  1.  The data that are being collected—Data that reflect how well patients’ needs are being met (ie, actual outcomes) have taken center stage, while data on amenities (eg, food and parking) are increasingly peripheral.
  2. How the data are being collected—Paper and telephone surveys are been supplemented or replaced by electronic methods. Increasingly, health care organizations are seeking email or other electronic ways of communicating with their patients. The reliability of collecting data via older methods is increasingly problematic, and electronic data collection reach patients faster and more efficiently. On average, respondents to electronic surveys are slightly younger than respondents to paper surveys, but the goal of measuring patient experience is to drive improvement; thus, more data is essential (see below).
  3. How much data are collected—The clear trend is away from seeking data from small samples of patients to meet some regulatory requirement, and toward seeking data from large samples of patients (ideally, giving all patients a chance to provide information). Larger amounts of data are needed to analyze data at the levels where true accountability lies, and true improvement can occur, such as the individual clinician’s performance.
  4. How the data are being used—A growing number of organizations are taking bold steps to increase accountability for improving patient experience, up to and including public reporting at an individual physician level. Many organizations are placing a modest financial incentive on improvement, while others use internal peer pressure as their approach. For example, physicians may undergo performance reviews annually at which their patient experience data as well as other performance metrics are discussed. Or organizations may share data internally without blinding, so that clinicians’ colleagues can see the ratings and comments made by patients.

Some of the most dramatic improvements have been made by organizations that have adopted the approach pioneered by the University of Utah Health System, which began sharing all patient ratings and comments on the internet in December 2012. Although Utah’s physicians were of course leery of the risks involved, they have found that the vast majority of patient comments were in fact laudatory—patients want to believe that clinicians are doing a good job, and have a low threshold for praising them. And the small percentage of criticisms from patients have proved powerful drivers of improvement. As a result, Utah and other organizations who are pursuing the transparency approach have seen improvement in patient experience far beyond what one could ever expect using financial incentives.

Summary

In sum, measurement of patient experience is no longer focused upon amenities such as food and parking based on responses from a few hundred patients. Instead, the field is about capturing important outcomes from as many patients as possible, so that teams and individual clinicians can improve their actual patient care. The strategic imperative to measure and manage these outcomes has never been greater; it is the antidote to a major side effect of medical progress, which is the chaos that characterizes modern health care. By asking patients about how their care is really going, I am certain we will respond and improve.

 

Corresponding author: Thomas H. Lee, MD, [email protected]. Dr. Lee is Chief Medical Officer for Press Ganey Associates, Inc.

From Press Ganey Associates, Inc., Wakefield, MA, and Harvard Medical School and Harvard School of Public Health, Boston, MA.

In fits and starts, but with increasing certainty, health care is changing its organizational focus from the activities of clinicians to meeting the needs of patients. That progress has been slowed and complicated, however, by lack of a performance framework that captures the extent to which patients’ needs are being met. In the absence of such data, “quality” has often been described in terms of the reliability of providers in complying with evidence-based guidelines.

Provider reliability is important, of course, but no substitute for the measurement and improvement of actual patient outcomes. After all, health care exists not to grade providers but to help patients. But clarity on that focus raises some important questions that we have not often discussed in the past.

What exactly are we trying to accomplish in health care? What is the goal? How can we tell how we are doing?

The answers cannot be found solely through measurement of “hard” clinical outcomes, such as death and disability. Yes, these are the most important focuses for improvement in health care, but we cannot deliver immortality, and we often can only delay complications of chronic disease. There is something else that our patients seek from health care, and it can only be measured by asking them directly.

 

Measuring "Peace of Mind"

That “something else” was described by one of my colleagues as “peace of mind that things are as good as they can be, given the cards that we have been dealt.” That may not be the most compact term in health policy, but I have yet to come up with something more concise— and it captures something immediately recognizable as important to anyone who has ever taken care of a patient with a serious disease, or spoken to that patient’s family. Of course, we should do our best to help patients live as long as possible, and of course we should optimize their health and relieve symptoms at every step of the way.

But there are other things that influence the degree of suffering that patients endure along that way, like hope, trust, anxiety, fear, and confusion. They are often considered part of the “art of medicine,” but I think we call them “art” because we are nervous about approaching them with discipline and rigor. In fact, these things can be measured, and managed—and the organizations that improve them are often rewarded with greater market share and professional pride.

Some of my clinician-colleagues do not immediately think of patients’ “peace of mind” as an important outcome, but when their family members or friends have medical problems, this issue immediately comes to the foreground. These clinicians do everything in their power to ensure that their special patients do not have to endure long delays or uncertainty about what is going to happen next, or reconcile conflicting advice, or wait for phone calls that will come…well, sometime soon. We know such experiences are part of what is often called the “disutility of care,” but when they happen to our intimates, we recognize it as something closer to torment.

The bad news is that the challenge of giving patients coordinated care gets harder every year, as medical progress introduces increasing complexity to health care. The good news is that we are in fact getting better at coordinating care every year, because we increasingly recognize the importance of the challenge, and are responding.

Data Collection Advances

One important first step in managing the coordination of care is measuring it. After all, only patients themselves can judge how adequately their needs have been met. And, until recently, the perspectives of patients could only be surmised, and clinicians were expected to improve their “bedside manners” on a case-by-case basis.

But that time has passed. Today, advances in health information systems and in communications technology allow data to be collected from patients at low costs; and for patients to be followed over time so that their outcomes can be measured, analyzed, and improved. Patients can be segmented into groups with similar shared needs, so that teams can be organized to meet those needs. Some of these needs are clearly clinical (eg, control of pain from diseases or treatments), while others are not directly related to patients’ medical problems but  are instead driven by how well health care providers work together.

Evolution of the health care marketplace has made improvement of value for those patient segments a strategic imperative. Provider organizations have to meet the needs of patients if they are to maintain or increase their market share—and, not coincidentally, these organizations are discovering that measurement and improvement of patient experience is an important strategic priority.

In this context, innovations are rapidly being adopted in 4 areas:

  1.  The data that are being collected—Data that reflect how well patients’ needs are being met (ie, actual outcomes) have taken center stage, while data on amenities (eg, food and parking) are increasingly peripheral.
  2. How the data are being collected—Paper and telephone surveys are been supplemented or replaced by electronic methods. Increasingly, health care organizations are seeking email or other electronic ways of communicating with their patients. The reliability of collecting data via older methods is increasingly problematic, and electronic data collection reach patients faster and more efficiently. On average, respondents to electronic surveys are slightly younger than respondents to paper surveys, but the goal of measuring patient experience is to drive improvement; thus, more data is essential (see below).
  3. How much data are collected—The clear trend is away from seeking data from small samples of patients to meet some regulatory requirement, and toward seeking data from large samples of patients (ideally, giving all patients a chance to provide information). Larger amounts of data are needed to analyze data at the levels where true accountability lies, and true improvement can occur, such as the individual clinician’s performance.
  4. How the data are being used—A growing number of organizations are taking bold steps to increase accountability for improving patient experience, up to and including public reporting at an individual physician level. Many organizations are placing a modest financial incentive on improvement, while others use internal peer pressure as their approach. For example, physicians may undergo performance reviews annually at which their patient experience data as well as other performance metrics are discussed. Or organizations may share data internally without blinding, so that clinicians’ colleagues can see the ratings and comments made by patients.

Some of the most dramatic improvements have been made by organizations that have adopted the approach pioneered by the University of Utah Health System, which began sharing all patient ratings and comments on the internet in December 2012. Although Utah’s physicians were of course leery of the risks involved, they have found that the vast majority of patient comments were in fact laudatory—patients want to believe that clinicians are doing a good job, and have a low threshold for praising them. And the small percentage of criticisms from patients have proved powerful drivers of improvement. As a result, Utah and other organizations who are pursuing the transparency approach have seen improvement in patient experience far beyond what one could ever expect using financial incentives.

Summary

In sum, measurement of patient experience is no longer focused upon amenities such as food and parking based on responses from a few hundred patients. Instead, the field is about capturing important outcomes from as many patients as possible, so that teams and individual clinicians can improve their actual patient care. The strategic imperative to measure and manage these outcomes has never been greater; it is the antidote to a major side effect of medical progress, which is the chaos that characterizes modern health care. By asking patients about how their care is really going, I am certain we will respond and improve.

 

Corresponding author: Thomas H. Lee, MD, [email protected]. Dr. Lee is Chief Medical Officer for Press Ganey Associates, Inc.

Issue
Journal of Clinical Outcomes Management - OCTOBER 2014, VOL. 21, NO. 10
Issue
Journal of Clinical Outcomes Management - OCTOBER 2014, VOL. 21, NO. 10
Publications
Publications
Article Type
Display Headline
Patient Experience Data Are Outcomes
Display Headline
Patient Experience Data Are Outcomes
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

“It’s Hard Work, but It’s Good for the Soul”: Accountable Care in the Trenches

Article Type
Changed
Display Headline
“It’s Hard Work, but It’s Good for the Soul”: Accountable Care in the Trenches

From Brigham and Women’s Hospital, Boston, MA.

 

I have always grazed on the medical commons [1]. My practice style was “accountable” years before I even knew what that meant. It wasn’t a conscious choice. It certainly wasn’t a statement about how the school district where my mom worked couldn’t afford to hire new teachers because of the rising cost of health care. When I finished medical training in 1991, I was more worried about killing a patient than about the patient losing health insurance if they left their job to start a business, let alone the downstream effects of that on the US economy.

I’ve just always had a value practice style. I never liked hospitals. I’m proud of my control issues, and there were just too many people, too much chaos, and too many opportunities for a medical error in the hospital. And it always seemed to me that most patients would rather feel lousy in their own bed, with a home-cooked meal and their family near, than in a hospital surrounded by strangers eating lousy food on an uncomfortable mattress (remember, I’m talking the 90s).

But my value bent is not just pro-home and anti-hospital. It’s my personal aesthetic of care. I enjoy the intellectual challenge of figuring out the right test to use to answer the question fastest with the least inconvenience for the patient. There is nothing quite like hitting upon the exact right medication regimen for a depressed alcoholic hypertensive diabetic patient with COPD and gout. And oh the joy when the patient calls and says their abdominal pain resolved on its own, meaning your plan to use watchful waiting rather than order an expensive abdominal CT of uncertain benefit saved the patient from unnecessary harm. Volume-driven care is a temptation to lazy thinking. Why would I want to do that?

I’ve been practicing for 23 years. I spent the bulk of my career practicing in what was arguably, in its time, the best Medicare ACO in the country—before anyone had invented the idea of an ACO [2]. I also led its department of general internal medicine in 2004 when the clinic decided to dis-integrate and de-capitate—transition from single-payer capitation to multipayer fee-for-service (oops!). In 2008, trying to understand why no medical students wanted to do what I love doing (being a general internist), I moved to an academic medical system and found myself back in the heart of fee-for-service medicine. And now, completing the circle, that same academic medical system is in the process of trying to move from volume to value, signing up to become a Medicare Pioneer ACO as well as entering into the Blue Cross Blue Shield of Massachusetts Alternative Quality Contract [3].

 

 

So how does it feel to practice in the trenches of an accountable care organization? Honestly, I’m not sure. First I’ll write what I do know: what it feels like to practice in a fee-for-service organization, and what it feels like to practice in a capitated organization.

Fee-for-service tempts one to do too much; capitation tempts one to do too little. The most ethical reimbursement proposal I’ve ever heard was that half of my patients would be fee-for-service and half capitated, and I wouldn’t find out which ones were which until the next year. No one would agree to write or sign that contract, but you can’t ignore its appeal.

Stylistically, I prefer capitation. I like the flexibility to think “outside the exam room” and do the right thing for the patient without having to worry about whether there is a relative value unit (RVU) tied to it. But value-based care is hard. The incentive in fee-for-service medicine is to see 2 healthy patients with sore throats and send the decompensating patient with multiple complex medical and psychosocial problems to the emergency room. The incentive in capitation is to add the complex patient on to the end of the schedule. In fee-for-service care, the metrics you are judged on are visits and RVUs. Nice and concrete—and something you can control. In capitation, the metrics are number of patients cared for and how much their care costs—a lot harder to measure, a lot more responsibility, and a lot less control since in the end it is the patient who takes the medication, gets the test done, sees the consultant, and changes their lifestyle. Or not.

I have never been particularly enamored of practicing in a pure fee-for-service system. Admittedly, I have only practiced in the CPT/RVU version of the fee-for-service system that has existed since the 1990s. An awfully weird version of fee-for-service if you ask me, since it only pays for one thing—me in a room with a patient. Not on the phone, not e-mailing, not video chatting. Not talking to their family, even if it’s in person. Not talking to the hospitalist, or ED doc, or their cardiologist.

Even weirder, it pays me a lot more for doing (procedures and tests) than for talking and thinking. And it refuses to pay many of the nonphysician clinicians I’ve worked with over the years for doing the same work, even if they can do it better than I can for less.

Continuing down the strangeness path, even if the system valued talking and thinking as much as I do, that’s not really what it pays me for. Instead, it pays me for documenting from a Chinese menu of CPT codes (one from column A, two from column B). Do I do 3 History of Present Illness (HPI) elements or 4? Did my Review of Systems contain 9 systems or 10? How many body systems did I examine? Why is it that a 99214 requires only 3 stable chronic diseases to max out my diagnostic/management options when it feels like most patients I see have so many more? Don’t I deserve a bonus for each additional one? And, not to hurt the feelings of whomever created this system, it takes a lot more time and energy to explain to the patient about false positives and the danger of doing an MRI for new-onset back pain than to just fill out the form and order it. Do they have any idea how long it takes to explain to a patient why antibiotics don’t cure viral infections? Yet I receive more medical decision-making points for ordering than not ordering the MRI or antibiotic. Really???

And, weirdest of all, they pay me whether or not I help the patient feel better or live a longer, healthier life. They even pay me for fixing my own complications.

As probably every parent in the world has told every child in the world, you get what you pay for. Nothing I’ve described above is actually paying me for the heart of what I do as a PCP—providing accessible, comprehensive, coordinated and continuous (person-focused care over time) care. Yes, at least for my generation, relationships are built, one-on-one in the exam room with the patient. But relationships require quality time together (ask your spouse), something that is hard to do when you are seeing patients every 15 minutes, and half that time is spent tapping away at a keyboard to meet CPT requirements (not to mention Meaningful Use and Joint Commission and every other regulatory body who wants a piece of my time with the patient).

In theory, it would be easy to construct a fee-for-service system that pays for many of the things I’ve mentioned above. I could be much more accessible if you paid me for email and video chats, plus a little extra to cover the cost of keeping the office open late on weekdays and opening on weekends. I could be much more comprehensive if you paid me to provide all the care the patient needed during a visit, not just what they came in for, and to build and work a registry to provide care between visits. I could be much more coordinated if you paid me (or the nurse or social worker I team with) to check in on patients and to communicate with the specialists and other clinicians my patients are seeing. Changing the reimbursement scheme so that I can focus on seeing only the patients who really need to be seen in person by a doctor, and paying enough for that visit so we can have the time together we need, would go a long way to building those all-important continuous relationships.

And some payers are trying to do this. Hence, new CPT codes from Medicare to report transitional care management (TCM) services for patients, and Blue Cross Blue Shield of Michigan making itself a nice return on investment and simultaneously improving quality of care by creating fee-for-service reimbursements that pay for only a small portion of the activities I mentioned above [4].

So when I say I prefer capitation to fee-for-service, what I’m really saying is I dislike the usual fee-for-service system, but I liked the capitation of the physician-led organization that was committed to value-based care and meeting the needs of the community it served [2]. Not the capitation I experienced in the first year and a half of my career, where there were no adjustments for patient complexity, no balancing quality measures, and no idea how to care manage a patient—a system where certain practices “won” by subtly pushing sick patients to seek care elsewhere.

Which brings me back to: How does it feel to practice in the trenches of an accountable care organization? Or specifically, what does it feel like to practice in an academic medical system 2 years into its transition into becoming an ACO?

In 2011, when ACOs were first appearing, they were compared to unicorns: everyone knows what they look like, but no one has actually seen one. Three years on, that seems a bit unfair. I suspect the current analogy should be that ACOs are like werewolves: they behave like fee-for-service organizations day-to-day, but at some mysterious reconciliation moment in the future, they magically turn into capitated organizations. As best as I can figure out, no full moon is involved.

 

 

What do I mean? I am lucky enough to spend 5/8 of my time practicing and 1/8 of my time leading a primary care innovation site for my employer—think Patient-Centered Medical Home on steroids. We’ve made it clear to everyone on the team that we are a Triple Aim–driven practice, and that our job is to keep people healthy, and by keeping them healthy we keep them out of the emergency department and the hospital. By being proactive, coordinating care, having same-day phone, email, and in-person access, staying open until 7 pm and opening on Saturday, booking on a 20-minute schedule, and by aggressively addressing our patients’ psychosocial issues on top of their medical issues, this hardy band of doctors, physician assistants, nurses, medical assistants, administrative assistants, social workers, pharmacist, nutritionist, and community health worker have spent our 3 years together improving population health, providing a great patient experience, and preventing more than enough unnecessary ED visits and hospital admissions to cover the cost of the team many times over. I look forward to going to work in the morning, and leave at night tired but satisfied.

One of our assumptions in designing the practice was that reimbursements would shift from volume to value. When we interviewed pharmacists and nutritionists, we were very clear that if they didn’t create value and if reimbursement didn’t change, we could not guarantee their jobs beyond 2 years. We were surprised, but also breathed a sigh of relief, when 4 months after we opened the organization signed the accountable care agreements. We wouldn’t be too far ahead of reimbursement reform, and if we just executed our vision we would easily financially justify our existence.

Oops. The organization was still being paid fee-for-service in real time. The monthly budget was still fee-for-service. That reconciliation of actual vs. expected cost of care was a theoretical event somewhere off in the future that no one knew how to divvy up. The cost of the extra team members was a current expense in the budget not matched by any revenue. We spent a lot of time explaining a very large variance.

Furthermore, a key financial metric for the organization is percentage of hospital beds occupied, while the practice is hoping to use percentage decrease in ambulatory-sensitive admissions as a metric of our economic success. It feels like a potential conflict, though thankfully this has never become a concern like the budget variance.

And by the way, 80% of our doctors’ clinical salary is still based on RVUs. And we’ve built a perfect system to minimize the docs’ RVUs. Easy visits are done by phone and email, slightly harder visits by the PAs. Visits to manage patients with 1 or 2 chronic diseases the pharmacist and nurses do. Doctors work at the top of their licenses, seeing patients with 5 to 10 problems who don’t fit into any protocol. But that top of the license still usually codes as a 99214. There are no RVUs for working with the team. So the need to generate RVUs (and the revenue that comes with them) remains a major constraint on the practice’s imagination.

Thankfully, there are many people in the organization who recognize our value beyond the revenue line in our budget. The team allows physicians to carry a much larger panel, so we talk about new patients to the system and downstream revenue to those who still think of us as a fee-for-service organization. For those who still live by the percent occupancy metric, we point out that the hospital is still full, and the medical admissions we tend to prevent wouldn't be nearly as profitable as the elective procedures that fill the beds instead. We take complex patients who are running amok through the system and bring them under control, allowing specialists to concentrate on what they do best. We take patients who can’t be discharged safely from the emergency room and inpatient floors because they lack the functioning primary care relationship needed for follow-up and see them within 3 days. And, to their credit, many people can think beyond this year’s budget, and even beyond the ACO reconciliation next year, to our mission of caring for populations.

And maybe, just maybe, that is why accountable care organizations will succeed. Because the people who run our ACO know our practice cares for a culturally diverse inner-city population where obesity and diabetes are huge problems. And they’ve seen our data that the nutritionist-pharmacist team is significantly lowering A1cs. So despite the budget variance they create, the organization keeps paying their salaries. Maybe because the mission of the organization includes meeting the medical needs of the community we serve. Maybe because those lower A1cs earn us quality bonuses. Maybe because those newly in-control diabetic patients make fewer visits to the ED and have fewer costly complications. I’m not sure it even matters why. What matters is they understand my practice and its population in a way that someone in Washington never will and never can.

Imagine if the practice was independent, and I wanted Medicare to pay my docs for working with the team and for all the phone and email care they provide. I wouldn’t even know where to start and, honestly, there is no chance it would happen. Of course, it hasn’t happened yet in the ACO I’m in. But at least in our ACO I know which human being to talk to, and that human being is also a doctor, and he knows my practice and the patients it serves. Yes, he’s my boss, and yes, he has bosses of his own, but at least we are having a dialogue about the possibility of tying less compensation to RVUs.

I tend to be skeptical. It’s a good internist skill. You don’t really want a doc who says, “I just saw it on Oprah, let’s give it a try.” I remain skeptical that ACOs will succeed. But if they do, it will be because they push the decisions about how to allocate resources much closer to the trenches.

Do I have concerns about the ACO in which I live? Plenty. I’ve already mentioned 3: the fact that we continue to budget like we are a fee-for-service organization, the need to “feed the beast” and keep the hospital full, and the disconnect between the system being paid for value while the doctors continue to be paid for volume. To be fair to the naysayers, most of our revenue still comes from fee-for-service reimbursement, with a small but rising percentage coming from ACO contracts. It’s hard to stand in 2 canoes. We have this huge, expensive FFS infrastructure—hospital beds, MRI machines, cath labs, etc. There is a leap of faith involved in hiring the people (RN care coordinators, nutritionists, pharmacists, social workers, and community health workers) who make up the “infrastructure” of an ACO. What if we don’t bend cost trend and having paid all these salaries also have to pay a penalty after we already decreased our day-to-day fee-for-service revenue? Even in the best case, it’s not like systems learn to provide value-based care overnight. So you are hiring the RN care managers now, but it could be years before you see a big enough drop off in visits to shelve the plans to expand the ED.

And all this involves eventually shifting resources from the ED to primary care, from inpatient to outpatient. No department is going to volunteer to do this. Even no-brainers, such as building systems that increase necessary fee-for-service revenue-generating care (screening mammograms and colonoscopies, for example) can create food fights. The most effective outreach to get patients in for these tests comes from the patient’s primary care team. But it takes time, and time is money. And after primary care spends that money, the revenue accrues to radiology and gastroenterology. How do you deal with that? And if you can’t deal with that, how do you divvy up any future bonus the system gets from splitting savings in total cost of care with the insurers?

 

 

I have this strong impression that the organization is trying as hard as possible to transform itself with an absolute commitment to not upsetting the very difficult  to recruit and retain specialists who fill the beds with all those high-paying elective procedures. If encouraging them to provide care in a less expensive setting within the ACO gets them upset, why risk finding out what happens when we ask them to fundamentally change how they spend their day, who they work with, and how they interact with patients?

But from my point of view in the trenches, it seems to me that we can’t really achieve accountable care until my day as a doctor, and the day of every nurse, pharmacist, social worker, administrative assistant, medical assistant, and administrator, feels fundamentally different than it did in a volume-based system. Patients make changes when it takes less energy to make the change than to maintain the status quo. Organizations aren’t any different. Primary care usually goes first in moving toward accountable care because the status quo is so dysfunctional. But primary care is only a fraction of the cost of care in the United States. The status quo for specialists, especially those procedural specialists, is pretty darned good. How many of them will make the leap, and how many will resist?

Society is entitled to some say in what it gets for its money. Meaning we, primary care and specialists alike, need to take responsibility for the societal benefits that the high cost of health care is forcing out: the new teacher not hired, the new business not started.

I don’t like change any more than any other doctor. Nor am I fully convinced that accountable care organizations are the right solution to the problems with fee-for-service medicine. But I do know that as doctors we have spent our careers making some pretty big sacrifices for our patients. Maybe I’m naive, but I do believe that most of us will agree to make massive changes in our day-to-day lives. But only after we’re convinced that those changes are the right thing for our patients and society, and hence the right thing for us.

Of course, I don’t need convincing; it’s the way I’ve always practiced. How many visits I’m going to do that day is not what gets me out of bed in the morning. I don’t want my lifetime RVU total on my gravestone. I went to medical school to help people, not to accumulate widgets of care.

So, where to start? I was talking with one of the younger docs in our practice a few weeks ago, asking how things were going. His response is the best argument I’ve ever heard for justifying transformation in the trenches from volume to value: “It’s hard work, but it’s good for the soul.”

 

Corresponding author: Stuart M. Pollack, MD, 301 S. Huntington Ave., Jamaica Plain, MA 02130, [email protected]

Financial disclosures: None.

References

1. Cassel CK, Brennan TE. Managing medical resources: return to the commons? JAMA 2007;297:2518–21.

2. Fallon Community Health Plan. Available at www.fchp.org/news/press-kit/summit-eldercare.aspx.

3. Chernew ME, Mechanic RE, Landon BE, Safran DG. Private-payer innovation in Massachusetts: the ‘alternative quality contract’. Health Aff (Millwood) 2011;30:51–61.

4. Paustian ML, Alexander JA, El Reda DK, et al. Partial and incremental PCMH practice transformation: implications for quality and costs. Health Serv Res 2014;49:52–74.

Issue
Journal of Clinical Outcomes Management - SEPTEMBER 2014, VOL. 21, NO. 9
Publications
Sections

From Brigham and Women’s Hospital, Boston, MA.

 

I have always grazed on the medical commons [1]. My practice style was “accountable” years before I even knew what that meant. It wasn’t a conscious choice. It certainly wasn’t a statement about how the school district where my mom worked couldn’t afford to hire new teachers because of the rising cost of health care. When I finished medical training in 1991, I was more worried about killing a patient than about the patient losing health insurance if they left their job to start a business, let alone the downstream effects of that on the US economy.

I’ve just always had a value practice style. I never liked hospitals. I’m proud of my control issues, and there were just too many people, too much chaos, and too many opportunities for a medical error in the hospital. And it always seemed to me that most patients would rather feel lousy in their own bed, with a home-cooked meal and their family near, than in a hospital surrounded by strangers eating lousy food on an uncomfortable mattress (remember, I’m talking the 90s).

But my value bent is not just pro-home and anti-hospital. It’s my personal aesthetic of care. I enjoy the intellectual challenge of figuring out the right test to use to answer the question fastest with the least inconvenience for the patient. There is nothing quite like hitting upon the exact right medication regimen for a depressed alcoholic hypertensive diabetic patient with COPD and gout. And oh the joy when the patient calls and says their abdominal pain resolved on its own, meaning your plan to use watchful waiting rather than order an expensive abdominal CT of uncertain benefit saved the patient from unnecessary harm. Volume-driven care is a temptation to lazy thinking. Why would I want to do that?

I’ve been practicing for 23 years. I spent the bulk of my career practicing in what was arguably, in its time, the best Medicare ACO in the country—before anyone had invented the idea of an ACO [2]. I also led its department of general internal medicine in 2004 when the clinic decided to dis-integrate and de-capitate—transition from single-payer capitation to multipayer fee-for-service (oops!). In 2008, trying to understand why no medical students wanted to do what I love doing (being a general internist), I moved to an academic medical system and found myself back in the heart of fee-for-service medicine. And now, completing the circle, that same academic medical system is in the process of trying to move from volume to value, signing up to become a Medicare Pioneer ACO as well as entering into the Blue Cross Blue Shield of Massachusetts Alternative Quality Contract [3].

 

 

So how does it feel to practice in the trenches of an accountable care organization? Honestly, I’m not sure. First I’ll write what I do know: what it feels like to practice in a fee-for-service organization, and what it feels like to practice in a capitated organization.

Fee-for-service tempts one to do too much; capitation tempts one to do too little. The most ethical reimbursement proposal I’ve ever heard was that half of my patients would be fee-for-service and half capitated, and I wouldn’t find out which ones were which until the next year. No one would agree to write or sign that contract, but you can’t ignore its appeal.

Stylistically, I prefer capitation. I like the flexibility to think “outside the exam room” and do the right thing for the patient without having to worry about whether there is a relative value unit (RVU) tied to it. But value-based care is hard. The incentive in fee-for-service medicine is to see 2 healthy patients with sore throats and send the decompensating patient with multiple complex medical and psychosocial problems to the emergency room. The incentive in capitation is to add the complex patient on to the end of the schedule. In fee-for-service care, the metrics you are judged on are visits and RVUs. Nice and concrete—and something you can control. In capitation, the metrics are number of patients cared for and how much their care costs—a lot harder to measure, a lot more responsibility, and a lot less control since in the end it is the patient who takes the medication, gets the test done, sees the consultant, and changes their lifestyle. Or not.

I have never been particularly enamored of practicing in a pure fee-for-service system. Admittedly, I have only practiced in the CPT/RVU version of the fee-for-service system that has existed since the 1990s. An awfully weird version of fee-for-service if you ask me, since it only pays for one thing—me in a room with a patient. Not on the phone, not e-mailing, not video chatting. Not talking to their family, even if it’s in person. Not talking to the hospitalist, or ED doc, or their cardiologist.

Even weirder, it pays me a lot more for doing (procedures and tests) than for talking and thinking. And it refuses to pay many of the nonphysician clinicians I’ve worked with over the years for doing the same work, even if they can do it better than I can for less.

Continuing down the strangeness path, even if the system valued talking and thinking as much as I do, that’s not really what it pays me for. Instead, it pays me for documenting from a Chinese menu of CPT codes (one from column A, two from column B). Do I do 3 History of Present Illness (HPI) elements or 4? Did my Review of Systems contain 9 systems or 10? How many body systems did I examine? Why is it that a 99214 requires only 3 stable chronic diseases to max out my diagnostic/management options when it feels like most patients I see have so many more? Don’t I deserve a bonus for each additional one? And, not to hurt the feelings of whomever created this system, it takes a lot more time and energy to explain to the patient about false positives and the danger of doing an MRI for new-onset back pain than to just fill out the form and order it. Do they have any idea how long it takes to explain to a patient why antibiotics don’t cure viral infections? Yet I receive more medical decision-making points for ordering than not ordering the MRI or antibiotic. Really???

And, weirdest of all, they pay me whether or not I help the patient feel better or live a longer, healthier life. They even pay me for fixing my own complications.

As probably every parent in the world has told every child in the world, you get what you pay for. Nothing I’ve described above is actually paying me for the heart of what I do as a PCP—providing accessible, comprehensive, coordinated and continuous (person-focused care over time) care. Yes, at least for my generation, relationships are built, one-on-one in the exam room with the patient. But relationships require quality time together (ask your spouse), something that is hard to do when you are seeing patients every 15 minutes, and half that time is spent tapping away at a keyboard to meet CPT requirements (not to mention Meaningful Use and Joint Commission and every other regulatory body who wants a piece of my time with the patient).

In theory, it would be easy to construct a fee-for-service system that pays for many of the things I’ve mentioned above. I could be much more accessible if you paid me for email and video chats, plus a little extra to cover the cost of keeping the office open late on weekdays and opening on weekends. I could be much more comprehensive if you paid me to provide all the care the patient needed during a visit, not just what they came in for, and to build and work a registry to provide care between visits. I could be much more coordinated if you paid me (or the nurse or social worker I team with) to check in on patients and to communicate with the specialists and other clinicians my patients are seeing. Changing the reimbursement scheme so that I can focus on seeing only the patients who really need to be seen in person by a doctor, and paying enough for that visit so we can have the time together we need, would go a long way to building those all-important continuous relationships.

And some payers are trying to do this. Hence, new CPT codes from Medicare to report transitional care management (TCM) services for patients, and Blue Cross Blue Shield of Michigan making itself a nice return on investment and simultaneously improving quality of care by creating fee-for-service reimbursements that pay for only a small portion of the activities I mentioned above [4].

So when I say I prefer capitation to fee-for-service, what I’m really saying is I dislike the usual fee-for-service system, but I liked the capitation of the physician-led organization that was committed to value-based care and meeting the needs of the community it served [2]. Not the capitation I experienced in the first year and a half of my career, where there were no adjustments for patient complexity, no balancing quality measures, and no idea how to care manage a patient—a system where certain practices “won” by subtly pushing sick patients to seek care elsewhere.

Which brings me back to: How does it feel to practice in the trenches of an accountable care organization? Or specifically, what does it feel like to practice in an academic medical system 2 years into its transition into becoming an ACO?

In 2011, when ACOs were first appearing, they were compared to unicorns: everyone knows what they look like, but no one has actually seen one. Three years on, that seems a bit unfair. I suspect the current analogy should be that ACOs are like werewolves: they behave like fee-for-service organizations day-to-day, but at some mysterious reconciliation moment in the future, they magically turn into capitated organizations. As best as I can figure out, no full moon is involved.

 

 

What do I mean? I am lucky enough to spend 5/8 of my time practicing and 1/8 of my time leading a primary care innovation site for my employer—think Patient-Centered Medical Home on steroids. We’ve made it clear to everyone on the team that we are a Triple Aim–driven practice, and that our job is to keep people healthy, and by keeping them healthy we keep them out of the emergency department and the hospital. By being proactive, coordinating care, having same-day phone, email, and in-person access, staying open until 7 pm and opening on Saturday, booking on a 20-minute schedule, and by aggressively addressing our patients’ psychosocial issues on top of their medical issues, this hardy band of doctors, physician assistants, nurses, medical assistants, administrative assistants, social workers, pharmacist, nutritionist, and community health worker have spent our 3 years together improving population health, providing a great patient experience, and preventing more than enough unnecessary ED visits and hospital admissions to cover the cost of the team many times over. I look forward to going to work in the morning, and leave at night tired but satisfied.

One of our assumptions in designing the practice was that reimbursements would shift from volume to value. When we interviewed pharmacists and nutritionists, we were very clear that if they didn’t create value and if reimbursement didn’t change, we could not guarantee their jobs beyond 2 years. We were surprised, but also breathed a sigh of relief, when 4 months after we opened the organization signed the accountable care agreements. We wouldn’t be too far ahead of reimbursement reform, and if we just executed our vision we would easily financially justify our existence.

Oops. The organization was still being paid fee-for-service in real time. The monthly budget was still fee-for-service. That reconciliation of actual vs. expected cost of care was a theoretical event somewhere off in the future that no one knew how to divvy up. The cost of the extra team members was a current expense in the budget not matched by any revenue. We spent a lot of time explaining a very large variance.

Furthermore, a key financial metric for the organization is percentage of hospital beds occupied, while the practice is hoping to use percentage decrease in ambulatory-sensitive admissions as a metric of our economic success. It feels like a potential conflict, though thankfully this has never become a concern like the budget variance.

And by the way, 80% of our doctors’ clinical salary is still based on RVUs. And we’ve built a perfect system to minimize the docs’ RVUs. Easy visits are done by phone and email, slightly harder visits by the PAs. Visits to manage patients with 1 or 2 chronic diseases the pharmacist and nurses do. Doctors work at the top of their licenses, seeing patients with 5 to 10 problems who don’t fit into any protocol. But that top of the license still usually codes as a 99214. There are no RVUs for working with the team. So the need to generate RVUs (and the revenue that comes with them) remains a major constraint on the practice’s imagination.

Thankfully, there are many people in the organization who recognize our value beyond the revenue line in our budget. The team allows physicians to carry a much larger panel, so we talk about new patients to the system and downstream revenue to those who still think of us as a fee-for-service organization. For those who still live by the percent occupancy metric, we point out that the hospital is still full, and the medical admissions we tend to prevent wouldn't be nearly as profitable as the elective procedures that fill the beds instead. We take complex patients who are running amok through the system and bring them under control, allowing specialists to concentrate on what they do best. We take patients who can’t be discharged safely from the emergency room and inpatient floors because they lack the functioning primary care relationship needed for follow-up and see them within 3 days. And, to their credit, many people can think beyond this year’s budget, and even beyond the ACO reconciliation next year, to our mission of caring for populations.

And maybe, just maybe, that is why accountable care organizations will succeed. Because the people who run our ACO know our practice cares for a culturally diverse inner-city population where obesity and diabetes are huge problems. And they’ve seen our data that the nutritionist-pharmacist team is significantly lowering A1cs. So despite the budget variance they create, the organization keeps paying their salaries. Maybe because the mission of the organization includes meeting the medical needs of the community we serve. Maybe because those lower A1cs earn us quality bonuses. Maybe because those newly in-control diabetic patients make fewer visits to the ED and have fewer costly complications. I’m not sure it even matters why. What matters is they understand my practice and its population in a way that someone in Washington never will and never can.

Imagine if the practice was independent, and I wanted Medicare to pay my docs for working with the team and for all the phone and email care they provide. I wouldn’t even know where to start and, honestly, there is no chance it would happen. Of course, it hasn’t happened yet in the ACO I’m in. But at least in our ACO I know which human being to talk to, and that human being is also a doctor, and he knows my practice and the patients it serves. Yes, he’s my boss, and yes, he has bosses of his own, but at least we are having a dialogue about the possibility of tying less compensation to RVUs.

I tend to be skeptical. It’s a good internist skill. You don’t really want a doc who says, “I just saw it on Oprah, let’s give it a try.” I remain skeptical that ACOs will succeed. But if they do, it will be because they push the decisions about how to allocate resources much closer to the trenches.

Do I have concerns about the ACO in which I live? Plenty. I’ve already mentioned 3: the fact that we continue to budget like we are a fee-for-service organization, the need to “feed the beast” and keep the hospital full, and the disconnect between the system being paid for value while the doctors continue to be paid for volume. To be fair to the naysayers, most of our revenue still comes from fee-for-service reimbursement, with a small but rising percentage coming from ACO contracts. It’s hard to stand in 2 canoes. We have this huge, expensive FFS infrastructure—hospital beds, MRI machines, cath labs, etc. There is a leap of faith involved in hiring the people (RN care coordinators, nutritionists, pharmacists, social workers, and community health workers) who make up the “infrastructure” of an ACO. What if we don’t bend cost trend and having paid all these salaries also have to pay a penalty after we already decreased our day-to-day fee-for-service revenue? Even in the best case, it’s not like systems learn to provide value-based care overnight. So you are hiring the RN care managers now, but it could be years before you see a big enough drop off in visits to shelve the plans to expand the ED.

And all this involves eventually shifting resources from the ED to primary care, from inpatient to outpatient. No department is going to volunteer to do this. Even no-brainers, such as building systems that increase necessary fee-for-service revenue-generating care (screening mammograms and colonoscopies, for example) can create food fights. The most effective outreach to get patients in for these tests comes from the patient’s primary care team. But it takes time, and time is money. And after primary care spends that money, the revenue accrues to radiology and gastroenterology. How do you deal with that? And if you can’t deal with that, how do you divvy up any future bonus the system gets from splitting savings in total cost of care with the insurers?

 

 

I have this strong impression that the organization is trying as hard as possible to transform itself with an absolute commitment to not upsetting the very difficult  to recruit and retain specialists who fill the beds with all those high-paying elective procedures. If encouraging them to provide care in a less expensive setting within the ACO gets them upset, why risk finding out what happens when we ask them to fundamentally change how they spend their day, who they work with, and how they interact with patients?

But from my point of view in the trenches, it seems to me that we can’t really achieve accountable care until my day as a doctor, and the day of every nurse, pharmacist, social worker, administrative assistant, medical assistant, and administrator, feels fundamentally different than it did in a volume-based system. Patients make changes when it takes less energy to make the change than to maintain the status quo. Organizations aren’t any different. Primary care usually goes first in moving toward accountable care because the status quo is so dysfunctional. But primary care is only a fraction of the cost of care in the United States. The status quo for specialists, especially those procedural specialists, is pretty darned good. How many of them will make the leap, and how many will resist?

Society is entitled to some say in what it gets for its money. Meaning we, primary care and specialists alike, need to take responsibility for the societal benefits that the high cost of health care is forcing out: the new teacher not hired, the new business not started.

I don’t like change any more than any other doctor. Nor am I fully convinced that accountable care organizations are the right solution to the problems with fee-for-service medicine. But I do know that as doctors we have spent our careers making some pretty big sacrifices for our patients. Maybe I’m naive, but I do believe that most of us will agree to make massive changes in our day-to-day lives. But only after we’re convinced that those changes are the right thing for our patients and society, and hence the right thing for us.

Of course, I don’t need convincing; it’s the way I’ve always practiced. How many visits I’m going to do that day is not what gets me out of bed in the morning. I don’t want my lifetime RVU total on my gravestone. I went to medical school to help people, not to accumulate widgets of care.

So, where to start? I was talking with one of the younger docs in our practice a few weeks ago, asking how things were going. His response is the best argument I’ve ever heard for justifying transformation in the trenches from volume to value: “It’s hard work, but it’s good for the soul.”

 

Corresponding author: Stuart M. Pollack, MD, 301 S. Huntington Ave., Jamaica Plain, MA 02130, [email protected]

Financial disclosures: None.

From Brigham and Women’s Hospital, Boston, MA.

 

I have always grazed on the medical commons [1]. My practice style was “accountable” years before I even knew what that meant. It wasn’t a conscious choice. It certainly wasn’t a statement about how the school district where my mom worked couldn’t afford to hire new teachers because of the rising cost of health care. When I finished medical training in 1991, I was more worried about killing a patient than about the patient losing health insurance if they left their job to start a business, let alone the downstream effects of that on the US economy.

I’ve just always had a value practice style. I never liked hospitals. I’m proud of my control issues, and there were just too many people, too much chaos, and too many opportunities for a medical error in the hospital. And it always seemed to me that most patients would rather feel lousy in their own bed, with a home-cooked meal and their family near, than in a hospital surrounded by strangers eating lousy food on an uncomfortable mattress (remember, I’m talking the 90s).

But my value bent is not just pro-home and anti-hospital. It’s my personal aesthetic of care. I enjoy the intellectual challenge of figuring out the right test to use to answer the question fastest with the least inconvenience for the patient. There is nothing quite like hitting upon the exact right medication regimen for a depressed alcoholic hypertensive diabetic patient with COPD and gout. And oh the joy when the patient calls and says their abdominal pain resolved on its own, meaning your plan to use watchful waiting rather than order an expensive abdominal CT of uncertain benefit saved the patient from unnecessary harm. Volume-driven care is a temptation to lazy thinking. Why would I want to do that?

I’ve been practicing for 23 years. I spent the bulk of my career practicing in what was arguably, in its time, the best Medicare ACO in the country—before anyone had invented the idea of an ACO [2]. I also led its department of general internal medicine in 2004 when the clinic decided to dis-integrate and de-capitate—transition from single-payer capitation to multipayer fee-for-service (oops!). In 2008, trying to understand why no medical students wanted to do what I love doing (being a general internist), I moved to an academic medical system and found myself back in the heart of fee-for-service medicine. And now, completing the circle, that same academic medical system is in the process of trying to move from volume to value, signing up to become a Medicare Pioneer ACO as well as entering into the Blue Cross Blue Shield of Massachusetts Alternative Quality Contract [3].

 

 

So how does it feel to practice in the trenches of an accountable care organization? Honestly, I’m not sure. First I’ll write what I do know: what it feels like to practice in a fee-for-service organization, and what it feels like to practice in a capitated organization.

Fee-for-service tempts one to do too much; capitation tempts one to do too little. The most ethical reimbursement proposal I’ve ever heard was that half of my patients would be fee-for-service and half capitated, and I wouldn’t find out which ones were which until the next year. No one would agree to write or sign that contract, but you can’t ignore its appeal.

Stylistically, I prefer capitation. I like the flexibility to think “outside the exam room” and do the right thing for the patient without having to worry about whether there is a relative value unit (RVU) tied to it. But value-based care is hard. The incentive in fee-for-service medicine is to see 2 healthy patients with sore throats and send the decompensating patient with multiple complex medical and psychosocial problems to the emergency room. The incentive in capitation is to add the complex patient on to the end of the schedule. In fee-for-service care, the metrics you are judged on are visits and RVUs. Nice and concrete—and something you can control. In capitation, the metrics are number of patients cared for and how much their care costs—a lot harder to measure, a lot more responsibility, and a lot less control since in the end it is the patient who takes the medication, gets the test done, sees the consultant, and changes their lifestyle. Or not.

I have never been particularly enamored of practicing in a pure fee-for-service system. Admittedly, I have only practiced in the CPT/RVU version of the fee-for-service system that has existed since the 1990s. An awfully weird version of fee-for-service if you ask me, since it only pays for one thing—me in a room with a patient. Not on the phone, not e-mailing, not video chatting. Not talking to their family, even if it’s in person. Not talking to the hospitalist, or ED doc, or their cardiologist.

Even weirder, it pays me a lot more for doing (procedures and tests) than for talking and thinking. And it refuses to pay many of the nonphysician clinicians I’ve worked with over the years for doing the same work, even if they can do it better than I can for less.

Continuing down the strangeness path, even if the system valued talking and thinking as much as I do, that’s not really what it pays me for. Instead, it pays me for documenting from a Chinese menu of CPT codes (one from column A, two from column B). Do I do 3 History of Present Illness (HPI) elements or 4? Did my Review of Systems contain 9 systems or 10? How many body systems did I examine? Why is it that a 99214 requires only 3 stable chronic diseases to max out my diagnostic/management options when it feels like most patients I see have so many more? Don’t I deserve a bonus for each additional one? And, not to hurt the feelings of whomever created this system, it takes a lot more time and energy to explain to the patient about false positives and the danger of doing an MRI for new-onset back pain than to just fill out the form and order it. Do they have any idea how long it takes to explain to a patient why antibiotics don’t cure viral infections? Yet I receive more medical decision-making points for ordering than not ordering the MRI or antibiotic. Really???

And, weirdest of all, they pay me whether or not I help the patient feel better or live a longer, healthier life. They even pay me for fixing my own complications.

As probably every parent in the world has told every child in the world, you get what you pay for. Nothing I’ve described above is actually paying me for the heart of what I do as a PCP—providing accessible, comprehensive, coordinated and continuous (person-focused care over time) care. Yes, at least for my generation, relationships are built, one-on-one in the exam room with the patient. But relationships require quality time together (ask your spouse), something that is hard to do when you are seeing patients every 15 minutes, and half that time is spent tapping away at a keyboard to meet CPT requirements (not to mention Meaningful Use and Joint Commission and every other regulatory body who wants a piece of my time with the patient).

In theory, it would be easy to construct a fee-for-service system that pays for many of the things I’ve mentioned above. I could be much more accessible if you paid me for email and video chats, plus a little extra to cover the cost of keeping the office open late on weekdays and opening on weekends. I could be much more comprehensive if you paid me to provide all the care the patient needed during a visit, not just what they came in for, and to build and work a registry to provide care between visits. I could be much more coordinated if you paid me (or the nurse or social worker I team with) to check in on patients and to communicate with the specialists and other clinicians my patients are seeing. Changing the reimbursement scheme so that I can focus on seeing only the patients who really need to be seen in person by a doctor, and paying enough for that visit so we can have the time together we need, would go a long way to building those all-important continuous relationships.

And some payers are trying to do this. Hence, new CPT codes from Medicare to report transitional care management (TCM) services for patients, and Blue Cross Blue Shield of Michigan making itself a nice return on investment and simultaneously improving quality of care by creating fee-for-service reimbursements that pay for only a small portion of the activities I mentioned above [4].

So when I say I prefer capitation to fee-for-service, what I’m really saying is I dislike the usual fee-for-service system, but I liked the capitation of the physician-led organization that was committed to value-based care and meeting the needs of the community it served [2]. Not the capitation I experienced in the first year and a half of my career, where there were no adjustments for patient complexity, no balancing quality measures, and no idea how to care manage a patient—a system where certain practices “won” by subtly pushing sick patients to seek care elsewhere.

Which brings me back to: How does it feel to practice in the trenches of an accountable care organization? Or specifically, what does it feel like to practice in an academic medical system 2 years into its transition into becoming an ACO?

In 2011, when ACOs were first appearing, they were compared to unicorns: everyone knows what they look like, but no one has actually seen one. Three years on, that seems a bit unfair. I suspect the current analogy should be that ACOs are like werewolves: they behave like fee-for-service organizations day-to-day, but at some mysterious reconciliation moment in the future, they magically turn into capitated organizations. As best as I can figure out, no full moon is involved.

 

 

What do I mean? I am lucky enough to spend 5/8 of my time practicing and 1/8 of my time leading a primary care innovation site for my employer—think Patient-Centered Medical Home on steroids. We’ve made it clear to everyone on the team that we are a Triple Aim–driven practice, and that our job is to keep people healthy, and by keeping them healthy we keep them out of the emergency department and the hospital. By being proactive, coordinating care, having same-day phone, email, and in-person access, staying open until 7 pm and opening on Saturday, booking on a 20-minute schedule, and by aggressively addressing our patients’ psychosocial issues on top of their medical issues, this hardy band of doctors, physician assistants, nurses, medical assistants, administrative assistants, social workers, pharmacist, nutritionist, and community health worker have spent our 3 years together improving population health, providing a great patient experience, and preventing more than enough unnecessary ED visits and hospital admissions to cover the cost of the team many times over. I look forward to going to work in the morning, and leave at night tired but satisfied.

One of our assumptions in designing the practice was that reimbursements would shift from volume to value. When we interviewed pharmacists and nutritionists, we were very clear that if they didn’t create value and if reimbursement didn’t change, we could not guarantee their jobs beyond 2 years. We were surprised, but also breathed a sigh of relief, when 4 months after we opened the organization signed the accountable care agreements. We wouldn’t be too far ahead of reimbursement reform, and if we just executed our vision we would easily financially justify our existence.

Oops. The organization was still being paid fee-for-service in real time. The monthly budget was still fee-for-service. That reconciliation of actual vs. expected cost of care was a theoretical event somewhere off in the future that no one knew how to divvy up. The cost of the extra team members was a current expense in the budget not matched by any revenue. We spent a lot of time explaining a very large variance.

Furthermore, a key financial metric for the organization is percentage of hospital beds occupied, while the practice is hoping to use percentage decrease in ambulatory-sensitive admissions as a metric of our economic success. It feels like a potential conflict, though thankfully this has never become a concern like the budget variance.

And by the way, 80% of our doctors’ clinical salary is still based on RVUs. And we’ve built a perfect system to minimize the docs’ RVUs. Easy visits are done by phone and email, slightly harder visits by the PAs. Visits to manage patients with 1 or 2 chronic diseases the pharmacist and nurses do. Doctors work at the top of their licenses, seeing patients with 5 to 10 problems who don’t fit into any protocol. But that top of the license still usually codes as a 99214. There are no RVUs for working with the team. So the need to generate RVUs (and the revenue that comes with them) remains a major constraint on the practice’s imagination.

Thankfully, there are many people in the organization who recognize our value beyond the revenue line in our budget. The team allows physicians to carry a much larger panel, so we talk about new patients to the system and downstream revenue to those who still think of us as a fee-for-service organization. For those who still live by the percent occupancy metric, we point out that the hospital is still full, and the medical admissions we tend to prevent wouldn't be nearly as profitable as the elective procedures that fill the beds instead. We take complex patients who are running amok through the system and bring them under control, allowing specialists to concentrate on what they do best. We take patients who can’t be discharged safely from the emergency room and inpatient floors because they lack the functioning primary care relationship needed for follow-up and see them within 3 days. And, to their credit, many people can think beyond this year’s budget, and even beyond the ACO reconciliation next year, to our mission of caring for populations.

And maybe, just maybe, that is why accountable care organizations will succeed. Because the people who run our ACO know our practice cares for a culturally diverse inner-city population where obesity and diabetes are huge problems. And they’ve seen our data that the nutritionist-pharmacist team is significantly lowering A1cs. So despite the budget variance they create, the organization keeps paying their salaries. Maybe because the mission of the organization includes meeting the medical needs of the community we serve. Maybe because those lower A1cs earn us quality bonuses. Maybe because those newly in-control diabetic patients make fewer visits to the ED and have fewer costly complications. I’m not sure it even matters why. What matters is they understand my practice and its population in a way that someone in Washington never will and never can.

Imagine if the practice was independent, and I wanted Medicare to pay my docs for working with the team and for all the phone and email care they provide. I wouldn’t even know where to start and, honestly, there is no chance it would happen. Of course, it hasn’t happened yet in the ACO I’m in. But at least in our ACO I know which human being to talk to, and that human being is also a doctor, and he knows my practice and the patients it serves. Yes, he’s my boss, and yes, he has bosses of his own, but at least we are having a dialogue about the possibility of tying less compensation to RVUs.

I tend to be skeptical. It’s a good internist skill. You don’t really want a doc who says, “I just saw it on Oprah, let’s give it a try.” I remain skeptical that ACOs will succeed. But if they do, it will be because they push the decisions about how to allocate resources much closer to the trenches.

Do I have concerns about the ACO in which I live? Plenty. I’ve already mentioned 3: the fact that we continue to budget like we are a fee-for-service organization, the need to “feed the beast” and keep the hospital full, and the disconnect between the system being paid for value while the doctors continue to be paid for volume. To be fair to the naysayers, most of our revenue still comes from fee-for-service reimbursement, with a small but rising percentage coming from ACO contracts. It’s hard to stand in 2 canoes. We have this huge, expensive FFS infrastructure—hospital beds, MRI machines, cath labs, etc. There is a leap of faith involved in hiring the people (RN care coordinators, nutritionists, pharmacists, social workers, and community health workers) who make up the “infrastructure” of an ACO. What if we don’t bend cost trend and having paid all these salaries also have to pay a penalty after we already decreased our day-to-day fee-for-service revenue? Even in the best case, it’s not like systems learn to provide value-based care overnight. So you are hiring the RN care managers now, but it could be years before you see a big enough drop off in visits to shelve the plans to expand the ED.

And all this involves eventually shifting resources from the ED to primary care, from inpatient to outpatient. No department is going to volunteer to do this. Even no-brainers, such as building systems that increase necessary fee-for-service revenue-generating care (screening mammograms and colonoscopies, for example) can create food fights. The most effective outreach to get patients in for these tests comes from the patient’s primary care team. But it takes time, and time is money. And after primary care spends that money, the revenue accrues to radiology and gastroenterology. How do you deal with that? And if you can’t deal with that, how do you divvy up any future bonus the system gets from splitting savings in total cost of care with the insurers?

 

 

I have this strong impression that the organization is trying as hard as possible to transform itself with an absolute commitment to not upsetting the very difficult  to recruit and retain specialists who fill the beds with all those high-paying elective procedures. If encouraging them to provide care in a less expensive setting within the ACO gets them upset, why risk finding out what happens when we ask them to fundamentally change how they spend their day, who they work with, and how they interact with patients?

But from my point of view in the trenches, it seems to me that we can’t really achieve accountable care until my day as a doctor, and the day of every nurse, pharmacist, social worker, administrative assistant, medical assistant, and administrator, feels fundamentally different than it did in a volume-based system. Patients make changes when it takes less energy to make the change than to maintain the status quo. Organizations aren’t any different. Primary care usually goes first in moving toward accountable care because the status quo is so dysfunctional. But primary care is only a fraction of the cost of care in the United States. The status quo for specialists, especially those procedural specialists, is pretty darned good. How many of them will make the leap, and how many will resist?

Society is entitled to some say in what it gets for its money. Meaning we, primary care and specialists alike, need to take responsibility for the societal benefits that the high cost of health care is forcing out: the new teacher not hired, the new business not started.

I don’t like change any more than any other doctor. Nor am I fully convinced that accountable care organizations are the right solution to the problems with fee-for-service medicine. But I do know that as doctors we have spent our careers making some pretty big sacrifices for our patients. Maybe I’m naive, but I do believe that most of us will agree to make massive changes in our day-to-day lives. But only after we’re convinced that those changes are the right thing for our patients and society, and hence the right thing for us.

Of course, I don’t need convincing; it’s the way I’ve always practiced. How many visits I’m going to do that day is not what gets me out of bed in the morning. I don’t want my lifetime RVU total on my gravestone. I went to medical school to help people, not to accumulate widgets of care.

So, where to start? I was talking with one of the younger docs in our practice a few weeks ago, asking how things were going. His response is the best argument I’ve ever heard for justifying transformation in the trenches from volume to value: “It’s hard work, but it’s good for the soul.”

 

Corresponding author: Stuart M. Pollack, MD, 301 S. Huntington Ave., Jamaica Plain, MA 02130, [email protected]

Financial disclosures: None.

References

1. Cassel CK, Brennan TE. Managing medical resources: return to the commons? JAMA 2007;297:2518–21.

2. Fallon Community Health Plan. Available at www.fchp.org/news/press-kit/summit-eldercare.aspx.

3. Chernew ME, Mechanic RE, Landon BE, Safran DG. Private-payer innovation in Massachusetts: the ‘alternative quality contract’. Health Aff (Millwood) 2011;30:51–61.

4. Paustian ML, Alexander JA, El Reda DK, et al. Partial and incremental PCMH practice transformation: implications for quality and costs. Health Serv Res 2014;49:52–74.

References

1. Cassel CK, Brennan TE. Managing medical resources: return to the commons? JAMA 2007;297:2518–21.

2. Fallon Community Health Plan. Available at www.fchp.org/news/press-kit/summit-eldercare.aspx.

3. Chernew ME, Mechanic RE, Landon BE, Safran DG. Private-payer innovation in Massachusetts: the ‘alternative quality contract’. Health Aff (Millwood) 2011;30:51–61.

4. Paustian ML, Alexander JA, El Reda DK, et al. Partial and incremental PCMH practice transformation: implications for quality and costs. Health Serv Res 2014;49:52–74.

Issue
Journal of Clinical Outcomes Management - SEPTEMBER 2014, VOL. 21, NO. 9
Issue
Journal of Clinical Outcomes Management - SEPTEMBER 2014, VOL. 21, NO. 9
Publications
Publications
Article Type
Display Headline
“It’s Hard Work, but It’s Good for the Soul”: Accountable Care in the Trenches
Display Headline
“It’s Hard Work, but It’s Good for the Soul”: Accountable Care in the Trenches
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default